PREFACE AMENDMENTS TO THE DRUG TARIFF March 2022, Study notes of Business

Download PREFACE AMENDMENTS TO THE DRUG TARIFF March 2022 and more Study notes Business in PDF only on Docsity! i 03/2022 PREFACE AMENDMENTS TO THE DRUG TARIFF March 2022 1. In accordance with regulation 89(3) of the National Health Service (Pharmaceutical and Local Pharma- ceutical Services) Regulations 2013 (“the 2013 Regulations”), the Secretary of State for Health as re- spects England and in accordance with regulation 41(4) of the National Health Service (Pharmaceutical Services) (Wales) Regulations 2013, the Welsh Ministers* as respects Wales have amended the Drug Tariff and determinations made in respect of the amendments to the Drug Tariff shall have effect from 1 August 2015. For England, by virtue of regulation 91(1) of the 2013 Regulations, the NHS Commissioning Board (“the Board”) has been appointed as a determining authority in relation to the pharmaceutical remuneration listed Schedule 8 to the 2013 Regulations (ie types of service remuneration) and remuneration for advanced services. This means that both the Secretary of State and the Board are able to determine remuneration in these areas, although if the Secretary of State determines remuneration in these areas, he is required to notify the Board of his intention to do so before doing so. As part of a phased transfer of responsibilities between the Secretary of State and the Board, the Board will be acting as the lead determining authority in relation to the following Parts: • Part IIIA • Part IIIB • Part VIA • Part VIB • Part VIC (up to Pharmaceutical Services (Advanced and Enhanced Services)(England) Directions 2013) By virtue of Part VIE, the Board is also a determining authority for England for the remuneration for enhanced services and acts as the lead determining authority in that area. The Secretary of State is the sole determining authority for all other Parts. Part XI, XIVD, XVIIID and XXI are rescinded in this edition of the Drug Tariff. Before the Secretary of State, NHS Commissioning Board and the Welsh Ministers make further determinations they will consult with such organisations as appear to be representative of persons to whose remuneration the determination would relate and such other persons as they consider appropriate in respect of determinations which relate to persons providing pharmaceutical services, or a category of such services in accordance with section 165 of the National Health Service Act 2006 and section 89 of the National Health Service (Wales) Act 2006, regulations made under those sections and under section 164 of the National Health Service Act 2006 and section 88 of the National Health Service (Wales) Act 2006. i) Effective date for all parts except those indicated in (ii) 1st day of the month ii) Effective date for specific provisions in specified parts N/A iii) Date of publication 1st day of the month TO: General Medical Practitioners, Pharmacy Contractors, Appliance Contractors ii 03/2022 PREFACE 2. Please note that you are now being supplied each month with the Drug Tariff which incorporates all amendments to date and this will continue until April 2021, when the Drug Tariff will no longer be printed and distributed (please see paragraph 4 for further information regarding these changes to the circulation of the Drug Tariff). All entries showing a change in price are not specifically included in this preface but are indicated in the Drug Tariff by L for price reduction and K for price increase; changes to the text re- lating to code, product description, or the inclusion of a new product are indicated by a vertical line in the margin. 3. While every effort is made to ensure that each monthly publication of the Drug Tariff includes all amendments made by the Secretary of State and the Welsh Ministers to the price applicable to the rele- vant period, the need to observe publishing deadlines sometimes defeats those efforts. Any omitted amendments will be effective from the date on which they came into force, even if publication of the details is unavoidably delayed. * Functions of the National Assembly for Wales have transferred to Welsh Ministers in accordance with section 162 of and paragraph 30 of Schedule 11 to the Government of Wales Act 2006. v 03/2022 PREFACE PAGE 31 Iasibon 50mg tablets PAGE 32 Levocarnitine 1g chewable tablets PAGE 40 Toremifene 60mg tablets PAGE 41 Venlafaxine oral solution sugar free (ALL) 5.8.2 PART VIIIA - BASIC PRICES OF DRUGS PAGE 271 PAGE 317 PAGE 334 PAGE 336 PAGE 343 PAGE 348 PAGE 349 PAGE 358 PAGE 366 S Special container * This pack only (others already available) Chlorpromazine 10mg tablets 28 1085 C Genesis Pharmaceuticals Ltd Ivermectin 10mg/g cream S 45 g 2743 C Soolantra Metoprolol 25mg tablets 28 2063 A Mometasone 25micrograms/dose / Olopatadine 600micrograms/ dose nasal spray S 240 dose 1332 C Ryaltris Olanzapine 10mg powder for solution for injection vials S 1 3595 C Zyprexa Paracetamol 500mg / Pseudoephedrine hydrochloride 30mg tablets 15 346 C Sinutab Non-Drowsy Paroxetine 40mg tablets 30 1555 A Rivaroxaban 1mg/ml oral suspension sugar free S 250 ml 1800 C Xarelto * Sodium zirconium cyclosilicate 10g oral powder sachets 30 31200 C Lokelma vi 03/2022 PREFACE PAGE 367 5.8.3 PART IXA - APPLIANCES PAGE 405 - ANAL IRRIGATION SYSTEM PAGE 418 - CATHETERS, ACCESSORIES PAGE 460 - DRESSINGS Wound Management Dressings Honey Based Topical Application PAGE 461 Hydrocolloid Dressing - Semi-permeable - Sterile - With Adhesive Border PAGE 473 Polyurethane Foam Film Dressing - Sterile - Without Adhesive Border Moderate to heavily exuding wounds PAGE 478 Protease Modulating Matrix - Sterile PAGE 491 Soft Silicone Wound Contact Dressing with Polyurethane Foam Film Backing - Sterile Sodium zirconium cyclosilicate 5g oral powder sachets 30 15600 C Lokelma o Products marked with this symbol must be dispensed with a supply of wipes and disposal bags oPeristeen Plus System - Cone (including toilet bag) 29160 7945 (System includes 1 control unit, 2 cone catheters, 1 water bag, 2 straps, 1 tube) oPeristeen Plus System - Cone (excluding toilet bag) 29161 7945 (System includes 1 control unit, 2 cone catheters, 1 water bag, 2 straps, 1 tube) oPeristeen Plus Accessory Unit - Cone 29162 13847 (Contains 15 cone catheters, 1 water bag) Skater Fix 8025 00 001 377 Revamil Wound Gel 5g 128 Hydraseal Border Square 5cm x 5cm (wound contact pad 4cm x 4cm + border 0.5cm) 70 10cm x 10cm (wound contact pad 8cm x 8cm + border 0.5cm) 136 15cm x 15cm (wound contact pad 12.5cm x 12.5cm + border 1.25cm) 280 20cm x 20cm (wound contact pad 18cm x 18cm + border 1cm) 470 Moderex Non-Adhesive Square 5cm x 5cm 45 20cm x 20cm 330 MaxioCel Square 10cm x 10cm 182 15cm x 15cm 344 Rectangular 2.5cm x 30cm 123 #AOne Silicone Foam Non-Border 5cm x 5cm 51 5cm x 7cm 57 7.5cm x 7.5cm 74 10cm x 10cm 117 12.5cm x 12.5cm 146 15cm x 15cm 231 20cm x 20cm 350 vii 03/2022 PREFACE PAGE 497 Soft Silicone Wound Contact Dressing with Polyurethane Foam Film Backing - Sterile With Silicone Adhesive Border PAGE 516 - EYE PRODUCTS Eye Drops - Hypromellose PAGE 523 - HYPODERMIC EQUIPMENT Reusable Pens For Insulin PAGE 645 - TRACHEOSTOMY AND LARYNGECTOMY APPLIANCES Tracheostomy Breathing Aids 5.8.4 PART IXC - STOMA APPLIANCES PAGE 726 - ADHESIVE REMOVERS (SPRAYS, LIQUIDS, WIPES) PAGE 908 - SKIN FILLERS AND PROTECTIVES (BARRIER CREAMS, PASTES, AEROSOLS, LOTIONS, POWDERS, GELS AND WIPES) #AOne Silicone Foam Border 7.5cm x 7.5cm 59 10cm x 10cm 93 12.5cm x 12.5cm 128 15cm x 15cm 170 17.5cm x 17.5cm 244 20cm x 20cm 316 Sacral 23cm x 23cm 444 Heel 23.5cm x 25cm 493 Tears Naturale II (15ml bottle) 270 NovoPen 6 (Blue) 3.0ml 1 unit (1-60 units) 2686 (Grey) 3.0ml 1 unit (1-60 units) 2686 (Novo Nordisk Ltd) NovoPen Echo Plus (Blue) 3.0ml 0.5 unit (0.5-30 units) 2686 (Red) 3.0ml 0.5 unit (0.5-30 units) 2686 (Novo Nordisk Ltd) Blom-Singer SpeakFree HME oHands-Free Valve with ClassicFlow BE1090EZ 690 oHands-Free Valve with EasyFlow BE1090EF 690 z These products qualify for the stoma customisation fee o Products marked with this symbol must be dispensed with a supply of wipes and disposal bags CliniMed Ltd CliniPeel Mint No Sting Medical Adhesive Remover 4502 50ml aerosol 675 Coloplast Ltd Brava Baby Adhesive remover 12014 30 sachets 1590 ConvaTec Ltd Esenta Sting Free Adhesive Remover Spray 423289 50ml 926 ConvaTec Ltd Esenta Sting Free Skin Barrier Spray 423288 50ml 1203 x 03/2022 PREFACE PAGE 318 PAGE 338 PAGE 350 5.9.3 PART VIIIB - ARRANGEMENTS FOR PAYMENT FOR SPECIALS AND IMPORTED UNLICENSED MEDICINES WITH A PRICE PER UNIT ABOVE A MINIMUM QUANTITY PAGE 393 5.9.4 PART IXA - APPLIANCES PAGE 405 - ANAL IRRIGATION SYSTEM PAGE 633 - STOCKINETTE Elasticated Tubular Bandage BP (Elasticated Surgical Tubular Stockinette; ESTS; Elasticated Stockinette) Basic Price p each Hypromellose 0.3% / Dextran '70' 0.1% eye drops 0.4ml unit dose preservative free 28 (7xS4) 1326 C Tears Naturale Ivermectin 10mg/g cream S 30 g 1829 C Soolantra Morphine 60mg modified-release granules sachets sugar free 30 5109 C MST Continus Paroxetine 40mg tablets 28 1448 A Pyridostigmine bromide 60mg/5ml oral suspension STD, SF, LF, NSF, AF, CF, FF 200ml 4167 30 Peristeen System 29121 8044 (System includes 1 control unit, 2 rectal catheters, 1 water bag, 2 straps) Peristeen System - small 29126 8044 (System includes 1 control unit, 2 rectal catheters, 1 water bag, 1 strap) Peristeen Accessory Unit 29122 14020 (Contains 15 rectal catheters, 1 water bag) Peristeen Accessory Unit - small 29127 14020 (Contains 15 rectal catheters, 1 water bag) Peristeen Rectal Catheters (Contains 10 rectal catheters) 29123 8963 Peristeen Rectal Catheters - small 29128 8963 (Contains 10 rectal catheters) per pair Peristeen Straps 29124 575 pack of 2 Peristeen Tubes 29125 804 Size 6.25cm 6.75cm 7.5cm 8.75cm 10.0cm 12.0cm Ref B C D E F G Quantity 0.5m 0.5m 0.5m 0.5m 0.5m 0.5m Tubigrip 103 112 112 124 124 129 xi 03/2022 PREFACE 5.9.5 PART IXC - STOMA APPLIANCES PAGE 725 - ADHESIVE PASTES, SPRAYS, SOLUTIONS PAGE 975 - UROSTOMY BAGS Hollister Ltd Moderma Flex CeraPlus Soft Convex Urostomy pouch with adhesive border, enhanced tap and viewing option 5.9.6 PART XV - BORDERLINE SUBSTANCES PAGE 1049 - LIST A Low-protein Products 5.10 OTHER CHANGES TO MARCH 2022 DRUG TARIFF 5.10.1 PART II - REQUIREMENTS ENABLING PAYMENTS TO BE MADE FOR THE SUPPLY OF DRUGS, APPLIANCES AND CHEMICAL REAGENTS PAGE 27 - DRUGS FOR WHICH DISCOUNT IS NOT DEDUCTED Individual Items Diethylstilbestrol tablets (ALL) Now Reads Diethylstilbestrol 1mg tablets 5.10.2 PART VIIIA - BASIC PRICES OF DRUGS PAGE 254 Now Reads PAGE 272 Now Reads Hollister Ltd Medical Adhesive Aerosol 7730 112ml 1816 pre-cut 20mm 59820 10 6632 Promin low-protein Promin Plus S Special container Amiloride 5mg/5ml oral solution sugar free 150 ml 4645 A Amiloride 5mg/5ml oral solution sugar free 150 ml 15885 C Essential Pharma Ltd Cimetidine 200mg/5ml oral solution sugar free 300 ml 4878 A Cimetidine 200mg/5ml oral solution sugar free 300 ml 4875 C Rosemont Pharmaceuticals Ltd xii 03/2022 PREFACE PAGE 301 Now Reads PAGE 305 Now Reads PAGE 336 Now Reads PAGE 344 Now Reads Now Reads PAGE 352 Now Reads PAGE 355 Now Reads Fluticasone propionate 250micrograms/dose / Salmeterol 50micrograms/ dose dry powder inhaler S 60 dose 3395 C Seretide 250 Accuhaler Fluticasone propionate 250micrograms/dose / Salmeterol 50micrograms/ dose dry powder inhaler S 60 dose 3395 C Glucose 40% oral gel 75 (3xS25) g 716 C GlucoGel Glucose 40% oral gel 75 (3xS25) g 716 C Mirtazapine 15mg/ml oral solution sugar free S 66 ml 8922 A Mirtazapine 15mg/ml oral solution sugar free S 66 ml 9789 C Rosemont Pharmaceuticals Ltd Omeprazole 10mg/5ml oral suspension sugar free S 75 ml 10393 A Omeprazole 10mg/5ml oral suspension sugar free S 75 ml 10646 C Rosemont Pharmaceuticals Ltd Omeprazole 20mg/5ml oral suspension sugar free S 75 ml 20110 A Omeprazole 20mg/5ml oral suspension sugar free S 75 ml 20600 C Rosemont Pharmaceuticals Ltd Posaconazole 100mg gastro- resistant tablets 24 59696 C Noxafil Posaconazole 100mg gastro- resistant tablets 24 59696 C Promazine 25mg/5ml oral solution 150 ml 5049 A Promazine 25mg/5ml oral solution 150 ml 6019 C Rosemont Pharmaceuticals Ltd 1 03/2022 CONTENTS Definitions ................................................................................................................................. 3 Part I Requirements for the Supply of Drugs, Appliances and Chemical Reagents .......... 4 Part II Requirements Enabling Payments to be made for the supply of Drugs, Appliances and Chemical Reagents................................................................................................ 17 Part IIIA Professional Fees (Pharmacy Contractors) ........................................................... 45 Part IIIB Scale of Fees (Appliance Contractors) .................................................................. 47 Part IV Consumables and Containers................................................................................ 48 Part V Deduction Scale (Pharmacy Contractors) .............................................................. 49 Part VIA Payment for Essential Services (Pharmacy Contractors) ...................................... 52 Part VIB Payment for Essential Services (Appliance Contractors)....................................... 67 Part VIC Advanced Services (Pharmacy and Appliance Contractors)(England) .................. 70 Part VID Advanced Services (Pharmacy and Appliance Contractors)(Wales) ................... 183 Part VIE Enhanced Services (Pharmacy Contractors) ....................................................... 221 Part VIIA Pharmacy Quality Scheme (England) .................................................................. 224 Part VIIB Collaborative Working Scheme (Wales)............................................................... 242 Part VIIC Quality and Safety Scheme (Wales) .................................................................... 244 Part VIID Rescinded - Intentionally Blank............................................................................ 247 Part VIIIA Basic Prices of Drugs........................................................................................... 248 Part VIIIB Arrangements for payment for Specials and Imported Unlicensed Medicines with a Price Per Unit Above a Minimum Quantity .......................................................... 384 Part VIIIC Arrangements of Payment for Products with a Nominal Price (England)............. 396 Part VIIID Arrangements for payment for Specials & Imported Unlicensed Medicines with Prices Determined Relative to a Commonly Identified Pack Size................................... 397 Part IX Appliances (Approved list of Appliances - Notes) ................................................ 400 Part IX Appliances (List of Technical Specifications) ....................................................... 401 Part IXA Appliances............................................................................................................ 402 Part IXB Incontinence Appliances ...................................................................................... 673 Part IXC Stoma Appliances ................................................................................................ 722 Part IXR Chemical Reagents.............................................................................................. 997 Part X Home Oxygen Therapy Service ......................................................................... 1001 Part XI Rescinded - Intentionally Blank.......................................................................... 1007 Part XIIA Pharmacy Access Scheme (England)................................................................ 1008 Part XIIB Essential Small Pharmacies Scheme (ESPS)(Wales) ....................................... 1013 Part XIII Payments in respect of Pre-Registration Trainees............................................. 1016 Part XIVA Reward Scheme - Fraudulent Prescription forms .............................................. 1017 Part XIVB Arrangements for Contractors Concerning Prescription Pricing Errors.............. 1020 Part XIVC Devolving the Global Sum - Temporary Safeguarding Payments...................... 1023 Part XIVD Rescinded - Intentionally Blank.......................................................................... 1025 Part XV Borderline Substances ....................................................................................... 1026 Part XVI Notes on Charges .............................................................................................. 1106 Part XVIIA Dental Prescribing.............................................................................................. 1124 Part XVIIB(i) Nurse Prescribers’ Formulary for Community Practitioners (in Wales District Nurses and Health Visitors) ............................................................................................ 1126 Part XVIIB(ii) Non-Medical Independent Prescribing (Nurses, Pharmacists, Optometrists, Physiother- apists and Chiropodists/Podiatrists) ................................................................... 1128 Part XVIIC National out-of-hours formulary.......................................................................... 1129 Part XVIIIA Drugs, Medicines and Other Substances not to be ordered under a General Medical Services Contract ............................................................................................... 1133 Part XVIIIB Drugs, Medicines and Other Substances that may be ordered only in certain circum- stances............................................................................................................... 1155 Part XVIIIC Criteria notified under the Transparency Directive ............................................. 1163 2 03/2022 CONTENTS Part XVIIID The National Health Service Litigation Authority (Pharmaceutical Remuneration - Over- payments) (England) Directions 2018................................................................ 1164 Part XIX Payments to Chemists Suspended by the NHS Commissioning Board or by Direction of the First-Tier Tribunal ..................................................................................... 1168 Part XX Requisitions and Private Prescriptions for Controlled Drugs.............................. 1173 Part XXI Rescinded - Intentionally Blank.......................................................................... 1175 3 03/2022 Definitions Definitions - DEFINITIONS (a) Except where the context otherwise requires, the terms to which a meaning is assigned by the Regulations or the Terms of Service have the same meaning in this Tariff. (b) The term ‘contractor’ has for Wales the same meaning as ‘chemist’ as defined in the National Health Service (Pharmaceutical Services) Regulations 1992 and for England the same meaning as ‘NHS chemist’ as defined in the National Health Service (Pharmaceutical and Local Pharmaceutical Services) Regulations 2013. LPS chemists will also need to be paid at least part of their remuneration (depending on the terms of their scheme) in accordance with the Drug Tariff, and so at least some references to ‘contractor’ will apply equally to them. (c) A pharmacy contractor is a person with whom the NHS Commissioning Board (NHSCB) for England and Local Health Board (LHB) for Wales has made arrangements for the provision of pharmaceutical services in respect of the supply of drugs, appliances and chemical reagents. (d) An appliance contractor is a person with whom the NHSCB for England and LHB for Wales has made arrangements for the provision of pharmaceutical services so far as it relates to the supply of appliances included within Part IXA/B/C of this Tariff. (e) The term persons includes a body of persons corporate or unincorporate. (f) The term Pricing Authority means, as the case may require, the NHS Business Services Authority (NHSBSA) or the NHS Wales Shared Services Partnership (NWSSP). (g) The term appliances as used in this Tariff includes dressings. (h) The term prescription refers to an item on a prescription form or dispensed in accordance with a repeatable prescription. (i) The term prescription form includes, where appropriate, a repeatable prescription. (j) The term pharmacy means any premises where drugs are provided by a pharmacist or pharmacy business as part of pharmaceutical services under section 126 (arrangements for pharmaceutical services) for England of the National Health Service Act 2006 and Section 80 of the National Health Service (Wales) Act 2006. (k) Specials are unlicensed medicinal products manufactured in the UK for human use which have been specially prepared to meet a prescription ordered for individual patients without the need for the manufacturer to hold a marketing authorisation for the medicinal product concerned. (l) Imported products are unlicensed medicinal products sourced from outside the UK under an importers licence issued by the MHRA. These products have been specially sourced to meet a prescription ordered for individual patients without the need for the importer to hold a marketing authorisation for the medicinal product concerned. In the preparation of this Tariff the Secretary of State for Health and the Welsh Ministers have consulted the Pharmaceutical Services Negotiating Committee. 6 03/2022 Part I REQUIREMENTS FOR THE SUPPLY OF DRUGS, APPLIANCES AND CHEMICAL REAGENTS Claims for payment for England only from November 2021 (October 2021 prescriptions)7 4. Paper prescriptions - contractors must: (a) Endorse prescription forms8 as required in Clause 9 (Endorsement Requirements) of this Tariff; and (b) Dispatch the prescription forms to the relevant division of the NHS Business Service Authority: NHS Prescription Services for England: (i) sorted as appropriate; (ii) in a secure manner that enables tracking and tracing of the delivery; and (iii) not later than the 5th day of the month following that in which the supply was made9. (c) Populate the appropriate claim form on the Manage Your Service (MYS) platform to reflect claims for paper prescription and submit it electronically by no later than the 5th day of the following month in which the supply was made10. Contractors must also print the populated FP34C form from the MYS platform and dispatch it alongside the paper prescriptions as per Clause 5A 4 (b). 5. Repeat dispensing services - contractors must: (a) endorse batch issues as required in Clause 9 (Endorsement Requirements) of this Tariff. In addition, batch issues relating to drugs, appliances or chemical reagents which have been dispensed must be stamped with the contractor's stamp and dated with the date on which the items were dispensed. (b) dispatch the batch issues relating to drugs, appliances or chemical reagents which have been dispensed to the NHS Prescription Services for England: (i) sorted as appropriate; (ii) in a secure manner that enables tracking and tracing of the delivery; and (iii) by no later than the 5th day of the month following that in which the supply was made11; (c) destroy any batch issues relating to drugs, appliances or chemical reagents which are not required, or which should not be dispensed because the contractor has been notified to that effect by the doctor who issued them or because the relevant repeatable prescription has expired; and (d) populate the appropriate claim form on the Manage Your Service (MYS) platform to reflect repeat dispensing services and submit it by no later than the 5th day of the following month in which the supply was made12. Contractors must also print the populated FP34C from the MYS platform and submit it alongside paper prescriptions as per Clause 5A 4 and 5. 7 Pharmacy contractors should note that until March 2022 two systems will be run concurrently – for those pharmacy contractors who wish to continue to use paper FP34C and receive payment as per Clause 5C1(a) and for those who wish to use MYS platform to populate their FP34C and receive payment as per Clause 5C1(d). From April 2022, only the timetable outlined in Clause 5 C1(d) will be in place (i.e. all pharmacy contractors will have to use MYS). 8 For the purpose of Part I of the Drug Tariff, wherever prescriptions, prescription forms or batch issues are mentioned, this includes prescription forms where supply was made in accordance with a Serious Shortage Protocol (SSP). 9 Where one or more bank holiday occurs within the first five days of the month, dispatch must be secured by the 6th of that month. Note: The requirement to submit EREMs within the first 5 days remains unchanged. 10 Where one or more bank holiday occurs within the first five days of the month, MYS submission must be completed and submitted by the 6th of the month. 11 Where one or more bank holiday occurs within the first five days of the month, dispatch must be secured by the 6th of that month. Note: The requirement to submit EREMs within the first 5 days remains unchanged. 12 Where one or more bank holiday occurs within the first five days of the month, MYS submission must be completed and submitted by the 6th of the month. 7 03/2022 Part I REQUIREMENTS FOR THE SUPPLY OF DRUGS, APPLIANCES AND CHEMICAL REAGENTS 6. Prescriptions via the Electronic Prescription Service - contractors must: (a) ensure that the Electronic Reimbursement Endorsement Messages (EREMs)13 include the endorsement requirements as required by Clause 9, Part II, and submit the EREMs via EPS to NHS Prescription Services for England for receipt at the Pricing Authority by no later than the 5th day of the month following that in which the supply was made14. Contractors should note that any EREMs sent after the 5th of the following month in which supply was made will be priced with next month’s claim. EREMs sent later than 180 days after the Dispense Notification was sent, will not be subject to payment; and (b) annotate the number of submitted EREMs on the appropriate claim form on the Manage Your Service (MYS) platform as per Clause 5A 4 and 515; and (c) all EPS tokens must be: (i) sorted separately from FP10 paper prescription forms with the exception of age exempt and any other tokens specified on the FP34C which must not be submitted (unless there is an exemption under Part XVI;) and (ii) dispatched in the same parcel as per Clause 5A 4 and 5. Contractors should note that EPS Tokens may be checked against claims for payment for audit purposes and possible enforcement action. The legal position is that payment will be made against the EREM, not the EPS token, and so prescription charges will be deducted, even if there is a failure to properly record an exemption that the patient can properly claim in the EREM, and if the EPS token correctly records this, unless contractors request a recheck under Part XIVB. It is a condition of entitlement to exemption from prescription charges that the patient or their representative claiming exemption must make and duly complete a declaration of entitlement unless an automatic exemption applies16. Where applicable, the contractor must ensure that the patient declaration is recorded on the system. In the case of automatic exemptions16, electronic prescriptions and paper prescriptions are similar, in that regardless of the exemption or charge information populated either by the patient/representative or the contractor, it will be disregarded (i.e. even if there is an error on the EREM, or the paper prescription states that a prescription charge was taken or if it is on a prescription with an additional chargeable item, the charge will not be deducted). 7. Claims in exceptional circumstances preventing the contractor from submitting the FP34C form as outlined in Clause 5A 4, 5 and 6. (a) In exceptional circumstances, where the contractor through no fault of their own, is unable to submit the FP34C form through the MYS portal, contractors are advised to contact the NHSBSA either through email nhsbsa.mys@nhs.net or by contacting the MYS helpdesk number (0300 330 1368). Contractors should note that this route is available only for emergencies, which are directly related to the contractor (for example internet outage in the contractor’s area) and not related to the MYS platform itself (in case of the MYS platform being down there will be instructions for contractors on the NHSBSA’s website on what to do); (b) Contractors, who will be using the email route, are advised that they must apply an advanced electronic signature to the email to secure payment; and (c) Contractors, who will be using the telephone route, are advised that the NHSBSA will contact the contractor via a preferred email address for the contractor, which the contractor has shared with them during the phone call conversation, for them to confirm that the claim the NHSBSA noted via the phone call was correct, and the contractor must apply an advanced electronic signature to the confirmation email to secure payment. 13 Pharmacy contractors should note that the Dispense Notification must be sent before the EREM. 14 Pharmacy contractors are encouraged to submit EREMs throughout the month. 15 Where one or more bank holiday occurs within the first five days of the month, dispatch must be secured by the 6th of that month. Note: The requirement to submit EREMs within the first 5 days remains unchanged. 16 This includes age exempt prescriptions, prescription forms with only free-of-charge sexual health medication and/or contraceptives, where Real Time Exemption Checking (RTEC) confirms an exemption and where a smaller quantity (in comparison with the prescription) of a drug is supplied in accordance with an SSP. 8 03/2022 Part I REQUIREMENTS FOR THE SUPPLY OF DRUGS, APPLIANCES AND CHEMICAL REAGENTS CLAUSE 5B **CALCULATION OF PAYMENTS 1. Pharmacy Contractors Payment for services provided by pharmacy contractors in respect of the supply of drugs, appliances and chemical reagents supplied against prescriptions at each separate place of business shall comprise:- (i) (a) The total of the prices of the drugs, appliances and chemical reagents so supplied calculated in accordance with the requirements of this Tariff. LESS *(b) An amount, based on the total of the prices at (i)(a) above, calculated from the table at Part V ("Deduction Scale"). AND (ii) The appropriate professional fee as set out in Part IIIA AND (iii) The allowance for consumables and containers as set out in Part IV. *NOTE 1 No deduction will be made in respect of prescriptions for items listed in Part II for which the contractor has not been able to obtain a discount. **NOTE 2 (Wales only) Payments in respect of October 1999 to March 2000. Contractors in agreement with LHBs in Wales who have notified the LHB that they accept the revised basis of calculation of payments for the period 1 October 1999 to 31 March 2000 set out in the National Assembly's offer letters on 20 November 2000 and 3 April 2001 shall be paid in accordance with the provisions of these letters. ***NOTE 3 (Wales only) Payments in respect of 1 October 2008 to 31 October 2008. Contractors in agreements with LHBs in Wales will be paid in accordance with the provisions of: Part VIA - Payment for Essential Services (Pharmacy Contractors), Part VIC - Advanced Services (Pharmacy Contractors), Medicines Use Review and Prescription Intervention Service, and Part XIII - Payments in respect of Pre Registration Trainees of the October 2008 edition of this Tariff as they apply in relation to England. 2. England only - Pharmacy Contractors - calculation of payments in exceptional circumstances (a) Calculation of payment for pharmacy contractors which submit FP34C and submit paper prescriptions after the 5th of the following month in which supply was made but before the date outlined in the following link – Pharmacy payment timetable | NHSBSA (i) Payment will be calculated as per Clause 5B1; (ii) From April 2022 (March 2022 prescriptions), the contractor will be contacted by the NHS Prescription Services for England, and unless the contractor provides evidence that the appropriate claim form was submitted as per Clause 5A 4, 5 and 6 and that the paper prescriptions were dispatched in line with Clause 5A 4, an administrative deduction of £25 will be made. This deduction reflects the administrative costs involved in NHSBSA calculating and making these payments. (iii) To prevent the administrative deduction mentioned above being made, the contractor must provide evidence, as outlined in Clause 5A 4, 5 and 6, of compliance with the submission requirements. Where evidence is submitted, no administrative deduction will be made. If no evidence is provided within this time, then the administrative deduction will be made from the next Schedule of Payment. (iv) In instances where the contractor does not provide the evidence, but the claiming process was followed as outlined in Clause 5A 4, 5 and 6, the contractor will have the opportunity to apply to have NHSBSA’s decision to make the administrative deduction mentioned in sub-paragraph (ii) above, overturned, by providing evidence and submitting it alongside an appropriate form available on NHSBSA’s website (Pharmacy payment timetable | NHSBSA). The contractor will need to submit the evidence and the appropriate form no later than one month after the month in which the administrative deduction was made. 11 03/2022 Part I REQUIREMENTS FOR THE SUPPLY OF DRUGS, APPLIANCES AND CHEMICAL REAGENTS (c) Pharmacy Earlier Payment Scheme (PEPS) (i) Pharmacy contractors, that are signed up to the Pharmacy Earlier Payment Scheme (the ‘Scheme’), should note that the Scheme will be terminated on 1 November 2021. Their last PEPS payment as outlined in Clause 5C 1(c)(iii) will be paid on 1 October 2021. (ii) On 1 November 2021 a period of a 12-month transition arrangement will start for pharmacy contractors, who are signed up to PEPS, to bring them over to the timetable outlined in Clause 5C (d) or (e). As part of the transition arrangement pharmacy contractors, who are signed up to the Scheme, will receive on 1 November 2021 a one- off payment to bridge the gap between the current PEPS payment timetable and the timetable outlined in Clause 5C (d) or (e). The one-off payment will be set at 92% of the PEPS pharmacy contractor’s payment which the contractor will have received on 1 October 2021. This one-off payment will be recovered in equal parts over 11 months, i.e. the last recovery will be on 30 September 2022. PEPS pharmacy contractors, who want to opt out from the above described transition arrangements, must notify the NHSBSA of this by 15 October 2021 by emailing nhsbsa.pepscontractorpayments@nhs.net requesting to opt out. (iii) Pharmacy contractors, who are enrolled on the Scheme will receive the following payment up until October 2021: • The NHSBSA will calculate a 100% advance payment to be paid to pharmacy contractors on the 1st of the month in respect of the items they expect to dispense in that month. This calculation will be based on the average number of items over the latest available 5 months, the average item value over the latest available 12 months and the prescription charge proportion from the latest available month (i.e. the percentage amount by which that month’s payment is reduced due to prescription charges). For example, April’s advance notice will be calculated using the average number of items from September 2020 to January 2021; the average item value from February 2020 to January 2021 and the prescription charge proportion from January 2021. • Batches must be received by the 5th day of the following month after dispensing as outlined in Clause 5A 1. For example, April’s batch must be sent to the NHSBSA by the 5th May. Failure to send a batch as described above may result in the contractor being removed from the PEPS Scheme and being therefore transferred to Timetable A. • Pharmacy contractors must immediately notify the NHSBSA of any adverse or anticipated changes pertaining to the pharmacy business. • Reconciliation payment – Pharmacy contractors will be paid the reconciliation payment according to Timetable A outlined above. Table 2 This table provides an overview of payment and reconciliation that will apply for the PEPS Scheme from July 2021. * If days referred to above fall on a weekend or bank holiday, the next available working day will be applied. Dispensing month July 2021 Aug 2021 Sept 2021 Oct 2021 Advance payment* 1 July 2 Aug 1 Sept 1 Oct Reconciliation for dispensed prescriptions 1 Oct 1 Nov 1 Dec 31 Dec 12 03/2022 Part I REQUIREMENTS FOR THE SUPPLY OF DRUGS, APPLIANCES AND CHEMICAL REAGENTS England only - From November 2021 (October 2021 prescriptions)18 Pharmacy Contractors will be paid monthly via NHSBSA. Payments will be detailed in the FP34 Schedule of Payment, which pharmacy contractors will receive approximately 5 working days before payment. (d) Payment timetable for pharmacy contractors that submit their batches and where the FP34C declaration is submitted via MYS by no later than the 5th of the month following that in which the supply was made. Pharmacy contractors will receive: (i) Advance Payment – 100% advance payment for prescriptions dispensed one month earlier paid from day 8 of the month the prescriptions and the appropriate claim form are submitted for pricing as per Clause 5A 4, 5 and 6 (see Table 3 below). This payment is based on the total items declared on the FP34C submission document and the latest available average Net Ingredient Cost (NIC) for that pharmacy, less the value of prescription charges collected and declared on the FP34C submission document. Formula for calculating estimated advance payment: Average Net Ingredient Cost of the prescriptions * x number of items declared on the submission document less the value of prescription charges declared as collected at the rate payable on the date of dispensing. (ii) Reconciliation Payment – • Positive reconciliation – pharmacy contractors will be paid the reconciliation payment on the 1st working day of the month two months after they have submitted the appropriate claim form and prescriptions for pricing. • Negative reconciliation – NHSBSA will recover the value of the overestimate from the 100% advance payment paid circa 6 working days later than the positive reconciliation (for exact dates see Table 3 below). Table 3 Payment timetable - From November 2021 (October 2021 prescriptions) for submissions made via MYS *Note - Where one or more bank holiday occurs within the first five days of the month, dispatch / submission must be secured by the 6th of that month. As a consequence, this will have an impact on the payment date, i.e. it will be 4 working days from the submission / dispatch date deadline. **Negative reconciliation will be recovered from the next advance payment due. 18 Pharmacy contractors should note that until March 2022 two systems will be run concurrently – for those pharmacy contractors who wish to continue to use paper FP34C and receive payment as per Clause 5C1(a) and for those who wish to use MYS platform to populate their FP34C and receive payment as per Clause 5C1(d). From April 2022, only the timetable outlined in Clause 5 C1(d) will be in place (i.e. all pharmacy contractors will have to use MYS). Advance for dispensed prescriptions Oct Nov Dec Jan Feb Mar Apr May Jun Jul Aug Sep Oct Nov Dec Jan Feb Planned advance payment date (4 working days after the submission/ dispatch deadline*) 11 Nov 21 9 Dec 21 11 Jan 22 10 Feb 22 10 Mar 22 11 Apr 22 11 May 22 9 Jun 22 11 Jul 22 11 Aug 22 9 Sep 22 11 Oct 22 10 Nov 22 9 Dec 22 11 Jan 23 9 Feb 23 9 Mar 23 Reconciliation month for dispensed prescriptions Sep Oct Nov Dec Jan Feb Mar Apr May Jun Jul Aug Sep Oct Nov Dec Jan ** Pay date for reconciled prescriptions - Payment due 1 Dec 21 31 Dec 21 1 Feb 22 1 Mar 22 1 Apr 22 29 Apr 22 1 Jun 22 1 Jul 22 1 Aug 22 1 Sep 22 30 Sep 22 1 Nov 22 1 Dec 22 30 Dec 22 1 Feb 23 1 Mar 23 3 Apr 23 13 03/2022 Part I REQUIREMENTS FOR THE SUPPLY OF DRUGS, APPLIANCES AND CHEMICAL REAGENTS (e) Payment timetable in exceptional circumstances (i) Payment timetable for pharmacy contractors that submit their batches after the 5th of the following month in which supply was made but before the date outlined in the following link – Pharmacy payment timetable | NHSBSA: Payments will be made monthly and comprise of the following elements: 1. An estimated 100% advance payment for prescriptions submitted one month earlier (dispensed two months earlier). This payment is based on the total items declared on the FP34C submission document and the latest available average Net Ingredient Cost (NIC) for that pharmacy, less the value of prescription charges collected and declared on the FP34C submission document; Formula for calculating estimated advance payment Average Net Ingredient Cost of the prescriptions * x number of items declared on the submission document less the value of the prescription charges declared as collected at the rate payable on the date of dispensing 2. plus the full value of the priced prescriptions submitted two months earlier (dispensed three months earlier); 3. minus the recovery of the estimated 100% advance payment paid the previous month related to the prescriptions submitted two months earlier (dispensed three months earlier). For example, August’s payment will comprise the 100% advance payment for prescriptions submitted in July (dispensed in June) with the full value of the priced prescriptions less the recovery of the estimated 100% advance payment for prescriptions submitted in June (dispensed in May). Table 4 Payment timetable in exceptional circumstances - From November 2021 (October 2021 prescriptions) (ii) Payment timetable for pharmacy contractors that submitted their batches after the date outlined in the following link - Pharmacy payment timetable | NHSBSA. Pharmacy contractors will receive payment with the next reconciliation payment (i.e. there will be no advance payment). For example: Example 1 - for prescriptions dispensed in November if the FP34C was submitted on 29 December, the pharmacy contractor would not receive the advance payment for November’s prescriptions on 1 January instead they would receive the reconciliation payment for November’s prescriptions on 1 February. Example 2 – for prescriptions dispensed in November if the paper prescriptions arrive at the NHSBSA on 29 December the pharmacy contractor would receive payment for these paper prescriptions according to the payment timetable for the reconciliation payment for December’s prescriptions i.e. on 1 March. Advance for dispensed prescriptions Oct Nov Dec Jan Feb Mar Apr May Jun Jul Aug Sep Oct Nov Dec Jan Feb Planned advance payment date 1 Dec 21 31 Dec 21 1 Feb 22 1 Mar 22 1 Apr 22 29 Apr 22 1 Jun 22 1 Jul 22 1 Aug 22 1 Sep 22 30 Sep 22 1 Nov 22 1 Dec 22 30 Dec 22 1 Feb 23 1 Mar 23 3 Apr 23 Reconciliation month for dispensed prescriptions Sep Oct Nov Dec Jan Feb Mar Apr May Jun Jul Aug Sep Oct Nov Dec Jan Pay date for reconciled prescriptions - Payment due 1 Dec 21 31 Dec 21 1 Feb 22 1 Mar 22 1 Apr 22 29 Apr 22 1 Jun 22 1 Jul 22 1 Aug 22 1 Sep 22 30 Sep 22 1 Nov 22 1 Dec 22 30 Dec 22 1 Feb 23 1 Mar 23 3 Apr 23 16 03/2022 Part I REQUIREMENTS FOR THE SUPPLY OF DRUGS, APPLIANCES AND CHEMICAL REAGENTS Table 2 Table 3 Pharmacy opened in May and submitted FP34C for May Pharmacy opened in May and did not submit FP34C for May but did so in June How the uplift should be calculated for the pharmacy? Must get the average each prescription got from £50 million for each prescription they dispensed in May. No uplift. However, the pharmacy contractor can demonstrate whether they provided NHS pharmaceutical services in May but failed to submit the batch so it could be considered whether they should access the uplift based on £50 million (see the reference to the appropriate form above). Pharmacy opened in June and submitted FP34C for June Pharmacy opened in June and did not submit FP34C for June but did so in July How the uplift should be calculated for the pharmacy? Must get the average each prescription got from £20 million for each prescription they dispensed in June. No uplift. However, the pharmacy contractor can demonstrate whether they provided NHS pharmaceutical services in June but failed to submit the batch so it could be considered whether they should access the uplift based on £20 million (see the reference to the appropriate form above). 17 03/2022 Part II REQUIREMENTS ENABLING PAYMENTS TO BE MADE FOR THE SUPPLY OF DRUGS, APPLIANCES AND CHEMICAL REAGENTS Part II - Requirements Enabling Payments to be made for the supply of Drugs, Appliances and Chemical Reagents CLAUSE 6 INFORMATION RELATING TO THE IDENTIFICATION OF THE PRESCRIBER Where a contractor provides the drugs or appliances ordered on any NHS prescription form, except forms issued by a Dental Practitioner, the Pricing Authority may return the prescription form to the contractor (as a referred back) if there is no prescriber code(s) present on the prescription form and request that the contractor seek the appropriate code(s). Where the contractor is able to identify the appropriate code(s), they shall endorse the prescription with the code and return it to the Pricing Authority. Where the contractor is unable to identify the appropriate code(s), they shall endorse the prescription to indicate that they have been unable to locate the code and return it to the Pricing Authority to be paid. Returned prescriptions shall be priced using the Drug Tariff relevant to the month in which the prescription is returned to the Pricing Authority. CLAUSE 7 PAYMENTS FOR DRUGS, APPLIANCES AND CHEMICAL REAGENTS A The price on which payment is based for a quantity of a drug, appliance or chemical reagent supplied is calculated proportionately from the basic price (see Clause 8 - Basic Price). B Subject to the provisions of Clause 10 (Quantity to be supplied) payment will be calculated on the basis that the exact quantity ordered by the prescriber has been supplied, apart from any supply made under a Serious Shortage Protocol (SSP) for a reduced or increased quantity. C Where a prescription form has been returned to the contractor for endorsement or elucidation and it is returned to the Pricing Authority unendorsed, or incompletely endorsed, or without further explanation, then the price for the drug, appliance or chemical reagent which it orders shall be determined by the Secretary of State for Health and Social Care and the Welsh Ministers. CLAUSE 8 BASIC PRICE A The basic price for those drugs, appliances and chemical reagents ordered by a name, or a synonym of that name, included in Parts VIII or IX shall be the price listed in the Drug Tariff. B In exceptional circumstances, where, in the opinion of the Secretary of State for Health and Social Care and the Welsh Ministers, there is no product available to contractors, at the price in Part VIII, claims for reimbursement for a product with a higher price than that listed may be accepted. Such claims shall be made by endorsement as set out in Clause 9C but only in the circumstances described in that Clause. If the Secretary of State for Health and Social Care and the Welsh Ministers are satisfied that the contractor was not able reasonably to obtain the product at a lower price, the basic price shall be the list price, for supplying to contractors, of the product and pack size so used, or such other price as the Secretary of State for Health and Social Care and the Welsh Ministers shall determine. The Secretary of State for Health and Social Care and the Welsh Ministers will publish details of any preparations to which this applies and the month(s) in which it applies. The Secretary of State for Health and Social Care and the Welsh Ministers may in addition specify the products for which endorsement will be accepted. C The basic price for a drug which is not listed in Part VIII of the Tariff shall be the list price, for supplying to contractors, of the pack size to be used for a prescription for that quantity, published by the manufacturer, wholesaler or supplier. In default of any such list price, the price shall be determined by the Secretary of State for Health and Social Care and the Welsh Ministers. D For SSP reimbursement and remuneration, refer to Clause 14. CLAUSE 9 ENDORSEMENT REQUIREMENTS A Contractors shall endorse prescription forms for drugs, appliances and chemical reagents listed in this Tariff as required by this Clause and when so required by the provisions of Part II Clauses 10 (Quantity to be Supplied) and 11 (Broken Bulk), Part III (Fees), Notes to Part VIIIB, Notes to Part VIIID and Note 2 to Part IXA/B/C (Appliances). B Prescriptions for drugs not listed in Part VIII of the Tariff shall be endorsed by the contractor with the pack size from which the order was supplied and, if the order is in pharmacopoeial or 'generic' form, with the brand name or the name of the manufacturer or wholesaler from whom the supply was purchased. Where the preparation is in Part VIIIA of the Tariff, endorsement of pack size is not necessary except for products in Category C that have more than one pack size listed. Where additional specific endorsement is necessary, contractors shall endorse prescription forms when so required by the provisions of Part II Clauses 10 (Quantity to be Supplied) and 11 (Broken Bulk), Part III (Fees) and Notes to Part VIIIB and Part VIIID. 18 03/2022 Part II REQUIREMENTS ENABLING PAYMENTS TO BE MADE FOR THE SUPPLY OF DRUGS, APPLIANCES AND CHEMICAL REAGENTS C Where the preparation is in Part VIII of the Tariff and, as described in Clause 8B, in the opinion of the Secretary of State for Health and Social Care and the Welsh Ministers there is no product available to contractors at the appropriate price, endorsements of brand name or of manufacturer or wholesaler of the product and pack size so used may be accepted. Contractors shall not so endorse unless they have made all reasonable efforts to obtain the product at the appropriate price but have not succeeded. The endorsement shall be initialled and dated by or on behalf of the contractor, and shall be further endorsed "no cheaper stock obtainable" or "NCSO" to indicate that the contractor has taken all such responsible steps. D Where a contractor supplies a quantity at variance with that ordered. i.e. under the provisions set out in Clause 10 (Quantity to be Supplied), the prescription shall be endorsed with the quantity supplied. E Until February 2022 (i.e. for January’s prescriptions claimed by 5 February), during the transition period, where a contractor supplies a product in accordance with a single dispensed product SSP (where a prescribed product is replaced by one product), the contractor must, in respect of - a non - electronic prescription forms - endorse the prescription form with “SSP” and the three-digit reference number of the specific SSP to indicate that a supply was made in accordance with a SSP, in addition to any other information required under Clause 9 (apart from Clause 9C). In the event that a pharmacy contractor endorses the prescription form with “NCSO” to indicate that a supply was made in accordance with a SSP, this will be accepted by the Pricing Authority for England during the transition period; and b electronic prescription forms, either - (i) where the SSP endorsement functionality is available on the pharmacy dispensing system, pharmacy contractors must indicate that a supply was made in accordance with a SSP on the Electronic Reimbursement Endorsement Message (EREM) by selecting “SSP”, entering the three-digit reference number of the specific SSP and endorsing the appropriate dispensed product and quantity, in addition to any other information required under Clause 9 (apart from Clause 9C); or (ii) where the SSP endorsement functionality is unavailable on the pharmacy dispensing system, pharmacy contractors must; • in the first instance endorse the EREM with “NCSO” and input into the endorsement field any other information required under Clause 9 (apart from Clause 9C); or • if the “NCSO” endorsement functionality is unavailable, indicate that a supply was made in accordance with a SSP on the EREM by selecting “ND” or ‘Not Dispensed’ and use the EPS token to endorse it with “SSP” and the three-digit reference number of the specific SSP, in addition to any other information required under Clause 9 (apart from Clause 9C). In the event that a pharmacy contractor endorses an EPS token with “NCSO” to indicate that a supply was made in accordance with a SSP this will be accepted during the transition period. The Pricing Authority for England will check that the EPS token matches the EREM. If a contractor submits multiple tokens linked to one EREM, only one will be used for pricing. Until February 2022 (i.e. for January’s prescriptions claimed by 5 February), during the transition period, where a contractor supplies a product in accordance with a multiple dispensed product SSP (where a prescribed product is replaced by two or more products), the contractor must, in respect of - c non - electronic prescription forms - endorse the prescription form with “SSP” and the three- digit reference number of the specific SSP to indicate that a supply was made in accordance with a SSP, in addition to any other information required under Clause 9 (apart from Clause 9C), for all products supplied under the SSP. In the event that a pharmacy contractor endorses the prescription form with “NCSO” to indicate that a supply was made in accordance with a SSP, this will be accepted by the Pricing Authority for England during the transition period; and d electronic prescription forms, either - (i) where the SSP endorsement functionality is available on the pharmacy dispensing system, pharmacy contractors must indicate that a supply was made in accordance with a SSP on the EREM by selecting “SSP”, entering the three-digit reference number of the specific SSP and endorsing the appropriate dispensed products and quantities, in addition to any other information required under Clause 9 (apart from Clause 9C) for each of the products dispensed under that SSP. Where the endorsement functionality does not allow for all 21 03/2022 Part II REQUIREMENTS ENABLING PAYMENTS TO BE MADE FOR THE SUPPLY OF DRUGS, APPLIANCES AND CHEMICAL REAGENTS CLAUSE 12 OUT OF POCKET EXPENSES Where, in exceptional circumstances, out-of-pocket expenses have been incurred in obtaining a drug, appliance or chemical reagent other than those priced in Part VIIIA Category A and M, Part VIIIB, Part VIIID, Part IXA, Part IXR of the Tariff and all other specials and imported products not listed and not required to be frequently supplied by the contractor, or where out-of-pocket expenses have been incurred in obtaining oxygen from a manufacturer, wholesaler or supplier specially for supply against a prescription, where such expenses on any occasion exceed 50p payment of the full amount may be made where the contractor sends a claim giving particulars to the Pricing Authority on the appropriate prescription form. The endorsement shall be ‘XP’ or ‘OOP’ to indicate the contractor has taken all reasonable steps to avoid claiming. CLAUSE 13 RECONSTITUTION OF CERTAIN ORAL LIQUIDS A This clause applies to antibacterial, antiviral or antifungal preparations listed in 5.1, 5.2 and 5.3 (except 5.3.1) of the British National Formulary (BNF), which are for oral administration and requires reconstitution from granules or powder. B When the quantity reconstituted from an original pack or packs is unavoidably greater than the quantity ordered and it has not been possible for the contractor to use the remainder for or towards supplying against another prescription, payment will be calculated from the Basic Price of the preparation and will be based on the nearest pack or number of packs necessary to cover the quantity ordered. CLAUSE 14 SERIOUS SHORTAGE PROTOCOL - REIMBURSEMENT AND REMUNERATION Any drugs, appliances or chemical reagents, which are supplied in line with a Serious Shortage Protocol (SSP), are to be reimbursed and remunerated as if they were dispensed in line with a prescription with the exception that items supplied in line with a SSP will attract an additional fee as per Part IIIA and the reimbursement price will account for VAT payment. To that end where a prescription or a prescription item is referred to in the Drug Tariff in the context of reimbursement or remuneration for dispensed drugs, appliances or chemical reagents, this is to be treated as applying to supply in line with a SSP. 22 03/2022 Part II REQUIREMENTS ENABLING PAYMENTS TO BE MADE FOR THE SUPPLY OF DRUGS, APPLIANCES AND CHEMICAL REAGENTS Drugs for which discount is not deducted Contractors who have not received discount in respect of the following products need not endorse the prescription. The prescription price reimbursement will have no discount deduction applied. GROUP ITEMS Cold Chain Storage (ALL) Controlled Drugs in schedules 1, 2 and 3 of the Misuse of Drugs Regulations 2001 Cytotoxic or Cytostatic items (ALL) Immunoglobulins (ALL) Insulins for Injection (ALL) Vaccines and Antisera (ALL) Unlicensed medicines not listed in Part VIIIB where the product has been sourced from a supplier holding a MHRA specials or importers licence (prescriptions must be endorsed with invoice price less discount/rebate) INDIVIDUAL ITEMS Abilify Maintena 400mg powder and solvent for prolonged-release suspension for injection pre-filled syringes Abilify Maintena 400mg powder and solvent for prolonged-release suspension for injection vials Acetic acid 33% liquid Acetic acid dilute 420microlitres/5ml oral solution sugar free Acetic acid glacial Acetone liquid Acetylcysteine 2g/10ml solution for infusion ampoules Acetylsalicylic acid (Aspirin powder) powder Aciclovir 200mg/5ml oral suspension sugar free Aciclovir 400mg/5ml oral suspension sugar free Acitretin 25mg capsules Aclasta 5mg/100ml infusion bottles Acumor XL 16mg capsules Acumor XL 24mg capsules A-CYS 600mg capsules A-CYS 600mg effervescent tablets A-CYS 600mg tablets Adartrel 2mg tablets Adcirca 20mg tablets Adefovir 10mg tablets Adempas tablets (ALL) Adoport capsules (ALL) Adrenaline (base) (1 in 10,000) dilute solution for injections ampoules (ALL) Adrenaline (base) 10mg/10ml (1 in 1,000) solution for injection ampoules Adrenaline (base) 5mg/5ml (1 in 1,000) solution for injection ampoules Adrenaline (base) solution for injection pre-filled disposable devices (ALL) Advagraf 1mg modified-release capsules Advagraf 3mg modified-release capsules Advagraf 5mg modified-release capsules Albunorm 5% solution for infusion 100ml bottles Alimemazine 10mg tablets Alimemazine 30mg/5ml oral solution Alimemazine 30mg/5ml oral solution sugar free Alimemazine 7.5mg/5ml oral solution Alimemazine 7.5mg/5ml oral solution sugar free Alimentum powder Alitretinoin capsules (ALL) Alkindi granules in capsules for opening (ALL) Almuriva 4.6mg/24hours transdermal patches Alpro Organic Soya Original milk Alpro Organic Soya Wholebean Unsweetened milk Alprostadil 20microgram powder and solvent for solution for injection cartridges Alprostadil 40microgram powder and solvent for solution for injection cartridges Alprostadil 20microgram powder and solvent for solution for injection vials Altraplen Compact Starter Pack liquid Altraplen Protein liquid 23 03/2022 Part II REQUIREMENTS ENABLING PAYMENTS TO BE MADE FOR THE SUPPLY OF DRUGS, APPLIANCES AND CHEMICAL REAGENTS Drugs for which discount is not deducted Altraplen Protein Starter Pack liquid Altrashot 120ml bottles Altrashot Starter Pack liquid Ambrisentan tablets (ALL) Amiloride 5mg/5ml oral solution sugar free Aminophylline 250mg/10ml solution for injection ampoules Ammonaps 500mg tablets Ammonaps 940mg/g granules Ammonia solution strong Ammonium bicarbonate powder Ammonium chloride powder Ampicillin 500mg powder for solution for injection vials Anise water concentrated Anquil 250microgram tablets APO-go PEN 30mg/3ml solution for injection APO-go PFS 50mg/10ml solution for infusion pre-filled syringes APO-go 50mg/5ml solution for injection ampoules Apomorphine 100mg/20ml solution for infusion vials Apomorphine 30mg/3ml solution for injection cartridges Apomorphine 30mg/3ml solution for injection pre-filled disposable devices Apomorphine 50mg/10ml solution for infusion pre-filled syringes Apomorphine 50mg/5ml solution for injection ampoules Apraclonidine 1% eye drops 0.25ml unit dose preservative free Apremilast 30mg tablets Aprepitant 125mg capsules and Aprepitant 80mg capsules Aptamil Pepti 1 powder Aptamil Pepti 2 powder Aptamil Pepti-Junior powder Arachis oil 130ml enema Arava 10mg tablets Arava 20mg tablets Arimidex 1mg tablets Aripiprazole 1mg/1ml oral solution sugar free Aripiprazole 400mg powder and solvent for suspension for injection pre-filled syringes Aripiprazole 400mg powder and solvent for suspension for injection vials Arixtra solution for injection pre-filled syringes (ALL) Arnica tincture Aromasin 25mg tablets Arpoya 10mg tablets Arpoya 5mg tablets Aspirin suppositories (ALL) Atomoxetine 4mg/ml oral solution sugar free Atomoxetine capsules (ALL) Atovaquone 750mg/5ml oral suspension sugar free Atripla 600mg/200mg/245mg tablets Atropine 1% eye drops Atropine 1mg/1ml solution for injection ampoules Atropine 3mg/10ml solution for injection pre-filled syringes Aubagio 14mg tablets Aymes ActaSolve High Energy powder 85g sachets Aymes ActaSolve High Energy Starter Pack powder Azilect 1mg tablets Baraclude tablets (ALL) Baraclude 0.05mg/ml oral solution Baricitinib tablets (ALL) Basecal200 oral powder 43g sachets Beclometasone 0.025% cream Beclometasone 0.025% ointment Beclometasone 5mg gastro-resistant modified-release tablets Benperidol 250microgram tablets Benzocaine powder 26 03/2022 Part II REQUIREMENTS ENABLING PAYMENTS TO BE MADE FOR THE SUPPLY OF DRUGS, APPLIANCES AND CHEMICAL REAGENTS Drugs for which discount is not deducted Co-codaprin 8mg/400mg dispersible tablets Co-danthramer 25mg/200mg/5ml oral suspension sugar free Co-danthrusate 50mg/60mg/5ml oral suspension sugar free Colesevelam 625mg tablets Colistimethate 1,662,500unit inhalation powder capsules Colistimethate 1million unit powder for solution for injection vials Colistimethate 2million unit powder for solution for injection vials Colobreathe 1,662,500unit inhalation powder capsules Colomycin 2million unit powder for solution for injection vials Combivir 150mg/300mg tablets Compleat Paediatric Complete Amino Acid Mix Powder Concord 693 250mg capsules Copper sulfate pentahydrate powder Cortiment 9mg modified-release tablets CosmoFer 500mg/10ml solution for injection ampoules Cresemba 100mg capsules Crystal violet powder BP 1980 Cystadane oral powder Cystagon capsules (ALL) Cystine500 oral powder sachets Dabigatran etexilate 150mg capsules Dabigatran etexilate 75mg capsules Dacepton 100mg/20ml solution for infusion vials Dacepton 30mg/3ml solution for injection cartridges Dalteparin sodium 10,000units/0.4ml solution for injection pre-filled syringes Dalteparin sodium 10,000units/1ml solution for injection pre-filled syringes Dalteparin sodium 100,000units/4ml solution for injection vials Dalteparin sodium 12,500units/0.5ml solution for injection pre-filled syringes Dalteparin sodium 15,000units/0.6ml solution for injection pre-filled syringes Dalteparin sodium 18,000units/0.72ml solution for injection pre-filled syringes Dalteparin sodium 5,000units/0.2ml solution for injection pre-filled syringes Dalteparin sodium 7,500units/0.3ml solution for injection pre-filled syringes Dalteparin sodium solution for injection ampoules (ALL) Dapsone tablets (ALL) Darunavir 800mg tablets DDAVP 0.1mg tablets Decapeptyl SR powder and solvent for suspension for injection vials (ALL) Deferasirox tablets (ALL) Deferiprone 1g tablets Degarelix powder and solvent for solution for injection vials (ALL) Demeclocycline 150mg capsules Descovy tablets (ALL) Denzapine 100mg tablets Desferal 500mg powder for solution for injection vials Desitrend 1000mg granules sachets Desitrend 500mg granules sachets Desitrend 500mg/5ml concentrate for solution for infusion ampoules Desmopressin 100microgram tablets Desmopressin 150micrograms/dose nasal spray Desmospray 10micrograms/dose nasal spray Dexamethasone 10mg/5ml oral solution sugar free Dexamethasone 20mg/5ml oral solution sugar free Dexamethasone 4mg tablets Deximune 100mg capsules Deximune 50mg capsules Diacomit capsules (ALL) Diacomit oral powder sachets (ALL) Dialamine powder Diazepam 2mg/5ml oral solution sugar free Dicycloverine tablets (ALL) 27 Part II 03/2022 REQUIREMENTS ENABLING PAYMENTS TO BE MADE FOR THE SUPPLY OF DRUGS, APPLIANCES AND CHEMICAL REAGENTS Drugs for which discount is not deducted Dicycloverine 10mg/5ml oral solution Diethylstilbestrol 1mg tablets Dificlir 200mg tablets Diflucan 200mg capsules Diflucan 200mg/5ml oral suspension Dipyridamole 50mg/5ml oral suspension sugar free Dithranol powder DocOmega oral powder 4g sachets Docusate 120mg/10g enema Dolutegravir tablets (ALL) Domperidone 1mg/ml oral suspension sugar free Donepezil 1mg/ml oral solution sugar free Donepezil orodispersible tablets (ALL) Dovato 50mg/300mg tablets Doxepin 25mg capsules Doxepin 50mg capsules Doxylamine 10mg / Pyridoxine 10mg gastro-resistant tablets Dronedarone 400mg tablets Duocal Super Soluble powder Dynastat 40mg powder and solvent for solution for injection vials Dynastat 40mg powder for solution for injection vials EAA Supplement oral powder 12.5g sachets Easiphen liquid E-Caps 200unit capsules E-Caps 400unit capsules Edurant 25mg tablets EleCare powder Elemental 028 Extra liquid Elemental 028 Extra powder Elive Cod Liver Oil 1000mg capsules Elmino XL 16mg capsules Elmiron 100mg capsules Eltrombopag tablets (ALL) Emend 125mg and 80mg capsules Emend 125mg oral powder sachets Emerade (1 in 1,000) solution for injection auto-injectors (ALL) Emsogen powder Emtricitabine / Tenofovir alafenamide tablets (ALL) Energivit powder Enoxaparin sodium 40mg/0.4ml solution for injection pre-filled syringes Enoxaparin sodium 60mg/0.6ml solution for injection pre-filled syringes Enoxaparin sodium 80mg/0.8ml solution for injection pre-filled syringes Enoxaparin sodium 100mg/1ml solution for injection pre-filled syringes Enoxaparin sodium 120mg/0.8ml solution for injection pre-filled syringes Enoxaparin sodium 150mg/1ml solution for injection pre-filled syringes Enoxaparin sodium 300mg/3ml solution for injection vials EN-Selenium 200microgram tablets Enshake oral powder 96.5g sachets Ensure Compact liquid Ensure liquid Ensure Plus Advance liquid Ensure Plus Commence liquid Ensure Plus Creme Ensure Plus Fibre liquid Ensure Plus Juce liquid Ensure TwoCal liquid EN-Taurine 500mg capsules Entecavir 50micrograms/ml oral solution sugar free Entocort 2mg/100ml enema Entresto tablets (ALL) Enzalutamide 40mg capsules 28 03/2022 Part II REQUIREMENTS ENABLING PAYMENTS TO BE MADE FOR THE SUPPLY OF DRUGS, APPLIANCES AND CHEMICAL REAGENTS Drugs for which discount is not deducted Epclusa 400mg/100mg tablets Epilim Chronosphere MR 100mg granules sachets Epilim Chronosphere MR 250mg granules sachets Epilim Chronosphere MR 500mg granules sachets Epilim Chronosphere MR 50mg granules sachets Epilim Intravenous 400mg powder and solvent for solution for injection vials EpiPen 300micrograms/0.3ml (1 in 1,000) solution for injection auto-injectors EpiPen Jr. 150micrograms/0.3ml (1 in 2,000) solution for injection auto-injectors Episenta 300mg/3ml solution for injection ampoules Epivir tablets (ALL) Erastig 13.3mg/24hours transdermal patches Erythromycin 1g powder for solution for infusion vials Esbriet 267mg capsules Esbriet tablets (ALL) Esmya 5mg tablets Essential Amino Acid Mix powder Ethanol 70% duty paid Ethanol 90% including duty Ethanol Absolute Duty Paid Ethosuximide 250mg capsules Ethosuximide 250mg/5ml oral solution sugar free Ether solvent Ethinylestradiol 10microgram tablets Ethinylestradiol 1mg tablets Ethinylestradiol 50microgram tablets Etonogestrel 68mg implant Eucalyptus oil liquid Eviplera 200mg/25mg/245mg tablets Evotaz 300mg/150mg tablets Exjade tablets (ALL) Extavia 300microgram powder and solvent for solution for injection vials Famciclovir 250mg tablets Famciclovir 500mg tablets Fampyra 10mg modified-release tablets Fareston 60mg tablets Femara 2.5mg tablets Feraccru 30mg capsules Ferinject solution for injection vials (ALL) Ferric chloride solution Ferric maltol (iron 30mg) capsules Ferriprox 1000mg tablets Ferrous sulfate heptahydrate powder Fidaxomicin 200mg tablets Fingolimod 500microgram capsules Firdapse 10mg tablets Firmagon powder and solvent for solution for injection vials (ALL) Flexible collodion methylated Flixotide Nebules (ALL) Flixotide 500micrograms/dose Accuhaler Flucloxacillin 1g powder for solution for injection vials Flucloxacillin 500mg powder for solution for injection vials Fluconazole 200mg/5ml oral suspension Fluconazole 200mg/100ml solution for infusion vials Fluoxetine 10mg capsules Fluticasone 250micrograms/dose / Formoterol 10micrograms/dose inhaler CFC free Fluticasone nebuliser liquid unit dose vials (ALL) Fluticasone propionate 500micrograms/dose dry powder inhaler Flutiform 250micrograms/dose / 10micrograms/dose inhaler Folic acid 5mg/5ml oral solution sugar free Follitropin alfa 75unit powder and solvent for solution for injection vials Follitropin alfa 450unit powder and solvent for solution for injection vials 31 Part II 03/2022 REQUIREMENTS ENABLING PAYMENTS TO BE MADE FOR THE SUPPLY OF DRUGS, APPLIANCES AND CHEMICAL REAGENTS Drugs for which discount is not deducted Hydrocortisone acetate 25mg/1ml suspension for injection ampoules Hydrocortisone granules in capsules for opening (ALL) Hydrocortisone powder Hydrocortisone 5mg modified-release tablets Hydrocortistab 25mg/1ml suspension for injection ampoules Hydrogen peroxide 35% solution Hydrogen peroxide 6% solution Hydrogen peroxide 9% solution Hydrolysed whey protein / Maltodextrin powder Hyoscine 1mg/72hours transdermal patches Iasibon 50mg tablets Ibandronic acid 3mg/3ml solution for injection pre-filled syringes Ichthammol liquid Idebenone 150mg tablets Ikervis 0.1% eye drops 0.3ml unit dose Imigran tablets (ALL) Imigran 20mg nasal spray Imigran Radis 100mg tablets Imigran Subject 6mg/0.5ml solution for injection pre-filled syringes with device Imigran Subject 6mg/0.5ml solution for injection syringe refill pack Imipramine 25mg/5ml oral solution sugar free Imnovid 2mg capsules Inclisiran 284mg/1.5ml solution for injection pre-filled syringes Indoramin 25mg tablets Industrial methylated spirit 70% Industrial methylated spirit 70%/Glycerol 1% gel Industrial methylated spirit 95% Industrial methylated spirit 99% Infatrini liquid Infatrini Peptisorb liquid Innohep 10,000units/0.5ml solution for injection pre-filled syringes Innohep 12,000units/0.6ml solution for injection pre-filled syringes Innohep 14,000units/0.7ml solution for injection pre-filled syringes Innohep 16,000units/0.8ml solution for injection pre-filled syringes Innohep 18,000units/0.9ml solution for injection pre-filled syringes Innohep 8,000units/0.4ml solution for injection pre-filled syringes Innohep solution for injection vials (ALL) Iodine alcoholic solution Iodine aqueous oral solution Iodine solution strong Iodoform compound paint BPC 1954 Iodoform powder BPC 1954 Iopidine 1% eye drops 0.25ml unit dose Ipecacuanha liquid extract Iron dextran 500mg/10ml solution for injection ampoules Isentress 400mg tablets Isocarboxazid 10mg tablets Isoleucine50 oral powder 4g sachets Isopropyl alcohol 70% / Hydrogen peroxide 0.125% liquid Isopropyl alcohol 70% / Hydrogen peroxide 0.125% spray Isopropyl alcohol 70% / Triclosan 0.5% topical solution Isopropyl alcohol (ALL) Isosorbide mononitrate 40mg modified-release tablets Isotretinoin 40mg capsules Ivabradine 2.5mg tablets Jaydess 13.5mg intrauterine device Jevity 1.5kcal liquid Jevity liquid Jevity Plus liquid Jevity Plus HP gluten free liquid Jevity Promote liquid 32 03/2022 Part II REQUIREMENTS ENABLING PAYMENTS TO BE MADE FOR THE SUPPLY OF DRUGS, APPLIANCES AND CHEMICAL REAGENTS Drugs for which discount is not deducted Jext solution for injection auto-injectors (ALL) Jorveza 1mg orodispersible tablets Jyseleca tablets (ALL) Kalydeco 150mg tablets Keppra 100mg/ml oral solution Keppra 500mg/5ml concentrate for solution for infusion vials Keppra 1g tablets Keppra 500mg tablets Keppra 750mg tablets KetoCal 2.5:1LQ liquid KetoCal 3:1 powder KetoCal 4:1 powder KetoCal 4:1 LQ liquid KetoClassic 3:1 Breakfast porridge KetoClassic 3:1 Meal bolognese 126g pouches KetoClassic 3:1 Meal chicken 135g pouches KetoClassic 3:1 Savoury meal Ketoconazole 200mg tablets KetoVie 4:1 liquid KeyOmega oral powder 4g sachets K.Yo semi-solid food 100g pots Kigabeq soluble tablets (ALL) Kindergen powder Kivexa 600mg/300mg tablets Klaricid IV 500mg powder for solution for infusion vials L-Arginine powder (Nutricia Ltd) Lacosamide 150mg tablets Lacosamide 200mg tablets Lactic acid liquid Lamictal dispersible tablets (ALL) Lamictal 100mg tablets Lamictal 200mg tablets Lamivudine tablets (ALL) Lamotrigine 2mg dispersible tablets sugar free Lanthanum carbonate chewable tablets (ALL) Lanthanum carbonate oral powder sachets (ALL) Larve Lavender oil liquid Leflunomide 15mg tablets Lemon spirit Lenalidomide 10mg capsules Lenalidomide 25mg capsules Lenalidomide 5mg capsules Lenalidomide 7.5mg capsules Lenograstim powder and solvent for solution for injection pre-filled syringes (ALL) Leucine100 oral powder sachets Leuprorelin 11.25mg powder and solvent for suspension for injection pre-filled syringes Levetiracetam 1g granules sachets sugar free Levetiracetam 100mg/ml oral solution sugar free Levetiracetam 500mg granules sachets sugar free Levetiracetam 500mg/5ml solution for infusion ampoules Levetiracetam 500mg/5ml solution for infusion vials Levocarnitine 1g chewable tablets Levocarnitine 1.5g/5ml oral solution paediatric Levomepromazine 6mg tablets Levonorgestrel 13.5mg intrauterine device Levonorgestrel 20micrograms/24hours intrauterine device Levosert 20micrograms/24hours intrauterine device Levothyroxine sodium 100micrograms/5ml oral solution sugar free Levothyroxine sodium 125micrograms/5ml oral solution sugar free Linezolid 100mg/5ml oral suspension 33 Part II 03/2022 REQUIREMENTS ENABLING PAYMENTS TO BE MADE FOR THE SUPPLY OF DRUGS, APPLIANCES AND CHEMICAL REAGENTS Drugs for which discount is not deducted Linezolid 600mg tablets Liothyronine 10microgram tablets Liothyronine 20microgram tablets Liothyronine 5microgram tablets Lipistart powder Liquigen emulsion Lisinopril 5mg/5ml oral solution sugar free Lithium carbonate 250mg tablets Locasol powder Lofepramine 70mg/5ml oral suspension sugar free Lokelma oral powder sachets (ALL) Lophlex powder 27.8g sachets Loprofin SNO-PRO drink Lorenzo’s oil Lotprosin XL capsules (ALL) Magenta powder Magstar 160mg capsules Malarivon 80mg/5ml syrup Malarone 250mg/100mg tablets Mannitol 40mg inhalation powder capsules with two devices Mastic compound paste Maraviroc tablets (ALL) Maviret 100mg/40mg tablets MCTprocal oral powder 16g sachets Mebeverine 50mg/5ml oral suspension sugar free Medrone 100mg tablets Medroxyprogesterone 400mg tablets Mefenamic acid 50mg/5ml oral suspension Meglumine amidotrizoate 3.3g/5ml / Sodium amidotrizoate 500mg/5ml oral solution sugar free Melatonin 1mg/ml oral solution sugar free Melatonin 2mg capsules Melatonin 3mg capsules Melatonin 5mg capsules Melatonin 5mg modified-release tablets Memantine 10mg/ml oral solution sugar free Menadiol 10mg tablets Menopur 75unit powder and solvent for solution for injection vials Menopur 150unit powder and solvent for solution for injection vials Menthol crystals Merional powder and solvent for solution for injection vials (ALL) Mercaptamine 150mg capsules Mercaptamine 50mg capsules Meronem powder for solution for injection vials (ALL) Mesalazine 1g/application foam enema Mesalazine 1g gastro-resistant tablets Mesalazine 1.6mg gastro-resistant tablets Mesalazine 400mg gastro-resistant tablets Mesalazine 800mg gastro-resistant tablets Metformin 500mg/5ml oral solution sugar free Methyl salicylate 25% liniment Methyl salicylate 50% ointment Methyldopa 125mg tablets Methylnaltrexone bromide 12mg/0.6ml solution for injection vials Methylprednisolone 100mg tablets Methylprednisolone sodium succinate 1g powder and solvent for solution for injection vials Metyrapone 250mg capsules Metoclopramide 5mg/5ml oral solution sugar free Metopirone 250mg capsules Midodrine 10mg tablets Midodrine 5mg tablets Mimpara tablets (ALL) 36 03/2022 Part II REQUIREMENTS ENABLING PAYMENTS TO BE MADE FOR THE SUPPLY OF DRUGS, APPLIANCES AND CHEMICAL REAGENTS Drugs for which discount is not deducted PaediaSure fibre liquid PaediaSure liquid PaediaSure Peptide liquid PaediaSure Plus liquid PaediaSure Plus fibre liquid PaediaSure Plus Juce liquid Paliperidone suspension for injection pre-filled syringe (ALL) Pamidronate disodium 90mg/6ml solution for infusion ampoules Pancrex V oral powder Pantoprazole 40mg powder for solution for injection vials Parecoxib 40mg powder and solvent for solution for injection vials Parecoxib 40mg powder for solution for injection vials Paricalcitol 1microgram capsules Paricalcitol 2microgram capsules Parvolex 2g/10ml concentrate for solution for infusion ampoules Pentacarinat 300mg powder for solution for injection vials Pentosan polysulfate sodium 100mg capsules Peppermint oil liquid Peppermint water concentrated Peptamen AF liquid Peptamen HN liquid Peptamen Junior Advance liquid Peptamen Junior liquid Peptamen Junior powder Peptamen liquid Peptamen liquid unflavoured Peptisorb liquid Perative liquid Perfalgan 1g/100ml solution for infusion vials Pericyazine 10mg/5ml oral solution Phenindione tablets 10mg Phenindione tablets 25mg Phenol crystals Phenol liquefied Phenoxybenzamine 10mg capsules Phenoxyethanol BP Phenylalanine50 oral powder sachets Phenylbutazone 100mg tablets Phenytoin sodium 250mg/5ml solution for injection ampoules Phenytoin sodium 300mg capsules Phlexy-10 drink mix Phlexy-10 tablets Phlexy-Vits powder Phlexy-Vits tablets Phosphates enema (Formula B) 128ml long tube Piperacillin / Tazobactam powder for solution for infusion vials (ALL) Pitolisant tablets (ALL) PK Aid 4 powder PKU Air15 liquid PKU Air20 liquid PKU Anamix First Spoon oral powder 12.5g sachets PKU Anamix Infant powder PKU Anamix Junior LQ liquid PKU Anamix Junior Powder PKU cooler10 liquid PKU cooler15 liquid PKU cooler20 liquid PKU Easy microtabs PKU Easy Shake & Go oral powder 34g sachets PKU explore10 oral powder 25g sachets PKU explore5 oral powder 12.5g sachets 37 Part II 03/2022 REQUIREMENTS ENABLING PAYMENTS TO BE MADE FOR THE SUPPLY OF DRUGS, APPLIANCES AND CHEMICAL REAGENTS Drugs for which discount is not deducted PKU express plus15 powder PKU express plus20 powder PKU gel powder PKU GMPro oral powder 33.3g sachets PKU Lophlex powder 28g sachets PKU Lophlex LQ 10 liquid PKU Lophlex LQ 20 liquid PKU Lophlex Sensation 20 PKU Maxamum oral powder sachets PKU Maxamum powder PKU sphere15 oral powder PKU sphere20 oral powder 35g sachets PKU squeezie liquid 85g pouches PKU start powder PKU Synergy oral powder 33g sachets Plenadren 5mg modified-release tablets Podophyllum resin powder Polyfusor SB sodium chloride 0.45% infusion 500ml bottles Polyfusor W water for injection bottles (ALL) Posaconazole 100mg gastro-resistant tablets Posaconazole 40mg/ml oral suspension Potassium chloride 15% (potassium 20mmol/10ml) solution for infusion 10ml ampoules Potassium iodide powder Potassium permanganate powder Pradaxa 150mg capsules Pradaxa 75mg capsules Pramipexole 350microgram tablets Prednisolone 20mg/application foam enema Pregestimil LIPIL powder Prezista 100mg/ml oral suspension Prezista 800mg tablets Primidone tablets (ALL) Pro-Cal shot Pro-Cal shot starter pack Proflavine hemisulfate powder Prograf capsules (ALL) Proguanil 100mg / Atovaquone 250mg tablets Promazine 25mg/5ml oral solution Promazine 50mg/5ml oral solution Prometax 4.6mg/24hours transdermal patches Propranolol oral solution sugar free (ALL) Propylthiouracil 50mg tablets ProSource liquid 30ml sachets ProSource jelly ProSource Plus liquid 30ml sachets Prostap 3 DCS 11.25mg powder and solvent for suspension for injection pre-filled syringes ProSure liquid Provera 400mg tablets ProZero liquid Psytixol 200mg/1ml solution for injection ampoules Pulmocare liquid Pyrid-10 tablets Pyrid-20 tablets Qtern 5mg/10mg tablets Quetiapine 300mg modified-release tablets Quetiapine 400mg modified-release tablets Quinagolide 75microgram tablets Qutenza 179mg cutaneous patches Ralnea XL 4mg tablets Ralnea XL 8mg tablets Raltegravir 400mg tablets 38 03/2022 Part II REQUIREMENTS ENABLING PAYMENTS TO BE MADE FOR THE SUPPLY OF DRUGS, APPLIANCES AND CHEMICAL REAGENTS Drugs for which discount is not deducted Rapamune tablets (ALL) Raponer XL 8mg tablets Raxone 150mg tablets Relistor 12mg/0.6ml solution for injection vials Renagel 800mg tablets Renapro powder Renapro Shot 60ml bottles Renastart powder Renastep liquid Renilon 7.5 liquid Renvela 800mg tablets Renvela 2.4g oral powder sachets ReQuip 1mg tablets ReQuip 2mg tablets ReQuip 5mg tablets ReQuip XL 8mg tablets Resonium A powder Resource Energy liquid Resource Fibre 2.0 liquid Resource Junior complete sip feed Respifor milkshake style liquid Revatio 10mg/ml oral suspension Revatio 20mg tablets Revlimid 10mg capsules Revlimid 25mg capsules Revlimid 5mg capsules Revlimid 7.5mg capsules Revolade tablets (ALL) Rezolsta 800mg/150mg tablets Rifabutin 150mg capsules Rifaximin tablets (ALL) Rilutek 50mg tablets Riluzole 25mg/5ml oral suspension sugar free Rinvoq 15mg modified-release tablets Riociguat tablets (ALL) Risperidone 1mg/ml oral solution sugar free Rivastigmine 2mg/ml oral solution Rivastigmine 2mg/ml oral solution sugar free Roaccutane 20mg capsules Rocephin 2g powder for solution for injection vials Ropinirole 2mg tablets Ropiqual XL 4mg tablets Rose water liquid Rotigotine transdermal patches (ALL) Rybelsus tablets (ALL) Sabril 500mg oral powder sachets Sacubitril/Valsartan tablets (ALL) Salbutamol 2mg tablets Salbutamol 4mg tablets Salbutamol 5mg/5ml solution for infusion ampoules Salicylic acid 12% collodion Salicylic acid powder Saline 0.9% nebuliser liquid 2.5ml Steri-Neb unit dose ampoules Salofalk 1g gastro-resistant tablets Salofalk 1g/application foam enema Salvacyl 11.25mg powder and solvent for suspension for injection vials Samsca tablets (ALL) Sandimmun 100mg/ml oral solution Sandimmun capsules (ALL) Saxagliptin 5mg / Dapagliflozin 10mg tablets Scandishake Mix oral powder 85g sachets 41 Part II 03/2022 REQUIREMENTS ENABLING PAYMENTS TO BE MADE FOR THE SUPPLY OF DRUGS, APPLIANCES AND CHEMICAL REAGENTS Drugs for which discount is not deducted Triamterene 50mg capsules Trientine dihydrochloride 300mg capsules Trifluoperazine oral solution sugar free (ALL) Trihexyphenidyl 5mg/5ml oral solution Trimipramine 50mg capsules Trimipramine tablets (ALL) Triptorelin 11.25mg powder and solvent for suspension for injection vials Triptorelin acetate 3mg powder and solvent for suspension for injection vials Triptorelin embonate 22.5mg powder and solvent for suspension for injection vials Triumeq 50mg/600mg/300mg tablets Truvada 200mg/245mg tablets Turpentine oil liquid TwoCal liquid TwoCal Bolus liquid TYR Anamix Infant powder TYR Anamix Junior LQ liquid TYR Anamix Junior oral powder sachets TYR cooler liquid TYR express15 oral powder 25g sachets TYR express20 oral powder 34g sachets TYR gel oral powder 24g sachets TYR Lophlex LQ 10 liquid TYR Lophlex LQ 20 liquid TYR Maxamum powder Uard 180XL capsules Uard 240XL capsules UCD amino5 oral powder 6.6g sachets Ulipristal 5mg tablets Urofollitropin 150unit powder and solvent for solution for injection vials Ursodeoxycholic acid 300mg tablets Ursofalk 250mg capsules Ursofalk 500mg tablets Valaciclovir 250mg tablets Valcyte 450mg tablets Valcyte 50mg/ml oral solution Valganciclovir 50mg/ml oral solution sugar free Valine50 oral powder 4g sachets Valtrex tablets (ALL) Vancomycin capsules (ALL) Vanquoral 100mg capsules Vanquoral 50mg capsules Vedrop 50mg/ml oral solution Vemlidy 25mg tablets Venlafaxine oral solution sugar free (ALL) Ventolin 5mg/5ml solution for infusion ampoules Verapamil 40mg/5ml oral solution sugar free Verkazia 0.1% eye drops 0.3ml unit dose VFEND 40mg/ml oral suspension VFEND tablets (ALL) Vigabatrin 500mg oral powder sachets sugar free Vigabatrin soluble tablets sugar free (ALL) Vimpat 150mg tablets Vimpat 200mg tablets Viread 123mg tablets Viread 245mg tablets Viread 33mg/g granules Viridal Duo Continuation Pack 20microgram powder and solvent for solution for injection cartridges Viridal Duo Continuation Pack 40microgram powder and solvent for solution for injection cartridges Vital 1.5kcal liquid Vitasavoury powder 50g sachets Voleze 4.6mg/24hours transdermal patches 42 Part II 03/2022 REQUIREMENTS ENABLING PAYMENTS TO BE MADE FOR THE SUPPLY OF DRUGS, APPLIANCES AND CHEMICAL REAGENTS Drugs for which discount is not deducted Volibris tablets (ALL) Voractiv tablets Voriconazole 200mg tablets Voriconazole 200mg/5ml oral suspension Wakix tablets (ALL) Warfarin 1mg/ml oral suspension sugar free (Rosemont Pharmaceuticals Ltd) Water for injections 1litre bottles Water for injections 500ml bottles Wellvone 750mg/5ml oral suspension White liniment Wilzin 25mg capsules Wilzin 50mg capsules Xagrid 500microgram capsules Xeljanz 5mg tablets Xeomin 100unit powder for solution for injection vials Xeplion suspension for injection pre-filled syringe (ALL) Xifaxanta 200mg tablets XMET Homidon powder XMTVI Asadon powder Xonvea 10mg/10mg gastro-resistant tablets XPhe jump 10 liquid XPHEN TYR Tyrosidon Free AA Mix powder Xyrem 500mg/ml oral solution Zalasta 20mg tablets Zeffix 100mg tablets Zemplar 1microgram capsules Zemplar 2microgram capsules Zinamide 500mg tablets Zinc acetate 25mg capsules Zinc acetate 50mg capsules Zinc oxide powder Zing 220mg capsules Zofran 16mg suppositories Zofran 4mg/5ml syrup Zofran Flexi-amp solution for injection ampoules (ALL) Zofran Melt oral lyophilisates (ALL) Zofran tablets (ALL) Zoladex 3.6mg implant SafeSystem pre-filled syringes Zoladex LA 10.8mg implant SafeSystem pre-filled syringes Zolmitriptan 5mg tablets Zometa 4mg/100ml infusion bottles Zometa 4mg/5ml solution for infusion vials Zonegran 100mg capsules Zonegran 50mg capsules Zonisamide 100mg capsules Zonisamide 50mg capsules Zovirax 200mg/5ml oral suspension Zovirax Double Strength 400mg/5ml oral suspension Zyprexa 10mg tablets Zyprexa 15mg tablets Zyprexa 20mg tablets Zyprexa 5mg tablets Zyprexa 7.5mg tablets Zyprexa Velotabs (ALL) Zytiga 500mg tablets Zyvox 100mg/5ml granules for oral suspension Zyvox 600mg tablets 43 03/2022 Part II REQUIREMENTS ENABLING PAYMENTS TO BE MADE FOR THE SUPPLY OF DRUGS, APPLIANCES AND CHEMICAL REAGENTS PRODUCTS INCLUDED IN CLAUSE 10B(iii) Products included in Clause 10B(iii) are listed below. Liquid preparations for external use: SubPara Name Pack(s) (c) Alphosyl Shampoo 2 in 1 (250ml) (c) Aveeno Body Wash (500ml) (c) Aveeno Lotion (500ml) (c) Aveeno Moisturising Creamy Oil (300ml) (a) Balneum Bath Oil (500ml and 1000ml) (a) Balneum Plus Bath Oil 82.95%/15% (500ml) (b) Capasal Therapeutic Shampoo (250ml) (c) Ceanel Concentrate (150ml and 500ml) (a) Cetraben Bath Oil (500ml) (c) Dentinox Cradle Cap Shampoo (125ml) (a) Dermalo Bath Emollient (500ml) (c) Dermol 200 Shower Emollient (200ml) (c) Dermol 500 Lotion (500ml pump) (c) Dermol 600 Bath Emollient (600ml) (c) Dermol Wash cutaneous emulsion (200ml) (a) Doublebase Emollient Bath Additive (500ml) (a) E45 Emollient Bath Oil (500ml) (c) E45 Lotion (200ml and 500ml pump) (c) E45 Shower Creme Emollient (200ml) (c) E45 Emollient Wash Cream (250ml) (c) Eczmol 1% Cream (250ml) (a) Emulsiderm Emollient (300ml and 1 litre) (b) Exorex Lotion (100ml and 250ml) (a) Hydromol Bath and Shower Emollient (350ml, 500ml and 1 litre) (c) Hydromol Intensive 10% Cream (30g and 100g) (b) Neutrogena T/Gel Shampoo for Dry Hair (125ml and 250ml) (b) Neutrogena T/Gel Therapeutic Shampoo (125ml and 250ml) (a) Oilatum Bath Formula (150ml and 300ml) (c) Oilatum Cream (150g, 500ml and 1050ml) (a) Oilatum Emollient (500ml) (a) Oilatum Junior Bath Additive (150ml, 300ml and 600ml) (c) Oilatum Junior Cream (150g and 350ml) (a) Oilatum Plus Bath Additive (500ml) (c) Oilatum Scalp Intensive Shampoo (100ml) (c) Oilatum Scalp Treatment Shampoo (100ml) (c) Oilatum Shower Gel Fragrance Free (150g) (b) Psoriderm Bath Emulsion (200ml) (b) Psoriderm Cream (225ml) (b) Psoriderm Scalp Lotion Shampoo (250ml) 46 Part IIIA 03/2022 PROFESSIONAL FEES (PHARMACY CONTRACTORS) See Part I, Clause 5B 1 (ii) (page 8) Fee per prescription p Endorsements required by contractors D. All prescriptions for oral liquid methadone attract a payment 250 NIL E. Where the quantity dispensed to the patient for a prescription for oral liquid methadone covers more than one dose and the contractor has packaged each dose separately 55 PD(n)* F. Where the prescription is for a Controlled Drug in Schedule 2 or 3 of the Misuse of Drugs Regulations 2001 Schedule 2 drug 128 NIL Schedule 3 drug 43 NIL G. Expensive Prescription Fee A fee equivalent to 2% of the net ingredient cost will be payable on all prescriptions over £100. Note - Expensive Prescription Fee is not included in calculation of ESPS payments *n=number of doses packaged separately minus the number of times the contractor has dispensed the medicine to the patient**. Where a numeric value is not provided, the contractor will be paid one fee. If the number of occasions when the medicine is dispensed equals the number of doses that have been packaged separately, this fee is not payable. ** an interaction with the patient where oral liquid methadone has been supplied. 47 03/2022 Part IIIB SCALE OF FEES (APPLIANCE CONTRACTORS) Part IIIB - Scale of Fees (Appliance Contractors) See Part I, Clause 5B 2(iii) (page 9) *Fee per prescription p Endorsements required by contractors * Endorsements under this heading apply only to claims for the appropriate professional fee. The endorsement codes to be used are: MF= Measured and Fitted Further endorsement may be necessary for other purposes eg Part II “CLAUSE 8 BASIC PRICE, “CLAUSE 9 ENDORSEMENT REQUIREMENTS” 1. ALL PRESCRIPTIONS attract a Professional Fee with a value of: 90 NIL 2. ADDITIONAL FEES: A. APPLIANCES (a) Elastic Hosiery (Compression Hosiery) requiring measurement and endorsed "measured and fitted" 260 MF (b) Trusses requiring measurement and endorsed "measured and fitted" 260 MF (c) Para stomal garments (belts and girdles) where size is not indicated in the Drug Tariff requiring measurement and endorsed “measured and fitted” 260 MF (d) Home delivery of Part IXA qualifying items1 (excluding catheter kits and intermittent self-catheters), Part IXB and Part IXC 340 NIL (e) Home delivery of catheter kits and intermittent self-catheters 930 NIL B. Expensive Prescription Fee A fee equivalent to 2% of the net ingredient cost will be payable on all prescriptions over £100. 1Part IXA (qualifying items) include: catheters (urinary and urethral), laryngectomy and tracheostomy, catheter accessories, catheter maintenance solutions, anal irrigation system, vacuum pumps and constrictor rings for erectile dysfunction, and wound drainage pouches. 48 03/2022 Part IV CONSUMABLES AND CONTAINERS Part IV - Consumables and Containers See Part I Clause 5B 1 (iii) 1. A Pharmacy Contractor shall supply in a suitable container any drug which he is required to supply under Part II of Schedule 2 to the Regulations. Capsules, tablets, pills, pulvules etc shall be supplied in airtight containers of glass, aluminium or rigid plastics; card containers may be used only for foil/strip packed tablets etc. For ointments, creams, pastes, card containers shall not be used Eye, ear and nasal drops shall be supplied in dropper bottles, or with a separate dropper where appropriate. 2. Payment for consumables used when dispensing is at the average rate of 1.24p per prescription for every prescription (except an oxygen prescription) supplied by contractors. This payment includes • Provision for supply of either a 5ml plastic measuring spoon (which shall comply with BS 3221:Part 6:1987), or a 1ml, 5ml or 10ml plastic oral syringe measure with every oral liquid medicine, except where the manufacturer’s pack includes one. Plastic oral syringe measures must be clearly labelled ‘oral’ and/or ‘enteral’ in a large font size, comply with appropriate British or European Standards (BS 3221:Part 7:1995 or an equivalent European Standard for the 5ml syringe) and be wrapped together with a bottle adaptor and instructions. Choice of whether a spoon or syringe (and its size) is supplied will depend on the nature of the medication regime. • In very exceptional circumstances, or where specifically requested by the prescriber, dilution may still take place. The prescription should be endorsed accordingly. • Provision for supply of a dropper bottle or separate dropper with every prescription for a medicine which is for administration to or via the ear, eye or nose, or a vaginal applicator with every prescription for contraceptive gel or cream, except where the manufacturer’s pack includes one. 3. Payment for containers will be at the rate of 10p for every prescription (except special containers) supplied where the quantity ordered is outside of the pack size (or a multiple of the pack size) for products: • Listed in Part VIIIA of the Tariff. • Not listed in Part VIIIA of the Tariff, the pack size published by the manufacturer, wholesaler or supplier is endorsed by or on behalf of the contractor. • Where the pack size is unknown by the Pricing Authority, the pack size endorsed by the contractor. For contractors who have dispensed any drug except for oral liquid methadone against an FP10MDA prescription form, as a temporary measure, for prescriptions dispensed from April 2013, this payment will be made once per instalment ie per dispensing to the patient, regardless of whether the quantity ordered per dispensing was available as a listed pack size. For oral liquid methadone, this payment will only be made where the total volume prescribed is outside a pack size listed in Part VIIIA Drug Tariff listed pack (or a multiple of). 4. Payment for consumables and containers is payable to pharmacy contractors only. 51 03/2022 Part V DEDUCTION SCALE (PHARMACY CONTRACTORS) 72001 72500 10.09 101501 102000 10.54 127001 127500 10.93 72501 73250 10.10 102001 102750 10.55 127501 128000 10.93 73251 73750 10.11 102751 103250 10.56 128001 128500 10.94 73751 74500 10.12 103251 103750 10.57 128501 129000 10.95 74501 75250 10.13 103751 104250 10.57 129001 129500 10.96 75251 75750 10.14 104251 104750 10.58 129501 130000 10.97 75751 76500 10.15 104751 105250 10.59 130001 130500 10.97 76501 77000 10.16 105251 105750 10.60 130501 131000 10.98 77001 77750 10.17 105751 106250 10.60 131001 131500 10.99 77751 78250 10.18 106251 106750 10.61 131501 132000 11.00 78251 79000 10.19 106751 107250 10.62 132001 132500 11.00 79001 79750 10.20 107251 107750 10.63 132501 133000 11.01 79751 80250 10.21 107751 108250 10.63 133001 133500 11.02 80251 81000 10.22 108251 108750 10.64 133501 134000 11.03 81001 81500 10.23 108751 109250 10.65 134001 134750 11.04 81501 82250 10.24 109251 109750 10.66 134751 135250 11.05 82251 82750 10.25 109751 110500 10.67 135251 135750 11.05 82751 83500 10.26 110501 111000 10.68 135751 136250 11.06 83501 84250 10.27 111001 111500 10.68 136251 136750 11.07 84251 84750 10.28 111501 112000 10.69 136751 137250 11.08 84751 85500 10.29 112001 112500 10.70 137251 137750 11.08 85501 86000 10.29 112501 113000 10.71 137751 138250 11.09 86001 86750 10.31 113001 113500 10.71 138251 138750 11.10 86751 87250 10.31 113501 114000 10.72 138751 139250 11.11 87251 88000 10.33 114001 114500 10.73 139251 139750 11.11 88001 88750 10.34 114501 115000 10.74 139751 140250 11.12 88751 89250 10.34 115001 115500 10.74 140251 140750 11.13 89251 90000 10.36 115501 116000 10.75 140751 141250 11.14 90001 90500 10.36 116001 116500 10.76 141251 141750 11.14 90501 91250 10.37 116501 117000 10.77 141751 142500 11.16 91251 91750 10.38 117001 117500 10.77 142501 143000 11.16 91751 92500 10.39 117501 118000 10.78 143001 143500 11.17 92501 93250 10.41 118001 118750 10.79 143501 144000 11.18 93251 93750 10.41 118751 119250 10.80 144001 144500 11.19 93751 94500 10.42 119251 119750 10.81 144501 145000 11.19 94501 95000 10.43 119751 120250 10.82 145001 145500 11.20 95001 95500 10.44 120251 120750 10.82 145501 146000 11.21 95501 96000 10.45 120751 121250 10.83 146001 146500 11.22 96001 96500 10.45 121251 121750 10.84 146501 147000 11.22 96501 97000 10.46 121751 122250 10.85 147001 147500 11.23 97001 97500 10.47 122251 122750 10.85 147501 148000 11.24 97501 98000 10.48 122751 123250 10.86 148001 149000 11.25 98001 98500 10.49 123251 123750 10.87 149001 150000 11.27 98501 99000 10.49 123751 124250 10.88 150001 160000 11.42 99001 99500 10.50 124251 124750 10.89 160001 & above 11.50 99501 100000 10.51 124751 125250 10.89 100001 100500 10.52 125251 125750 10.90 100501 101000 10.52 125751 126500 10.91 101001 101500 10.53 126501 127000 10.92 Monthly Total of Prices £ Deduction Rate % Monthly Total of Prices £ Deduction Rate % Monthly Total of Prices £ Deduction Rate % From To From To From To 52 03/2022 Part VIA PAYMENT FOR ESSENTIAL SERVICES (PHARMACY CONTRACTORS) Part VIA - Payment for Essential Services (Pharmacy Contractors) 1. Establishment Payments Wales only 1.1 Pharmacy contractors who dispense the stated number of prescription items or more in any month will receive an Establishment Payment from 1 April 2005. 1.2 In Wales, pharmacy contractors who dispense 2,500 prescription items or more in any month will receive an Establishment Payment as set out in the table below: 1.3 The Establishment Payment will be paid monthly, calculated as 1/12th of the payment, on the basis of the number of prescription items submitted, and reimbursed by the Pricing Authority, in the relevant month. 1.4 Where total monthly payments in relation to prescriptions passed for pricing for the period April to March are less than the amount which would have been paid had the payment been calculated on an annual basis, pharmacy contractors may make a claim for a top up payment to the LHB for Wales. They should submit, by the following 30 November, copies of WP34 statements for the relevant period (April to March) as evidence of the total number of prescription items passed for pricing during this period. 2. Practice Payments Wales only 2.1 All pharmacy contractors in Wales only will receive a Practice Payment from 1 April 2005. 2.2 Practice Payments from 1 April 2020 to 30 September 2020, which includes a contribution for provision of auxiliary aids for people eligible under the Equality Act 2010 (EA) and, will be as set out in the table below: 2.3 Practice Payments from 1 October 2020 to 31 December 2020, which includes a contribution for provision of auxiliary aids for people eligible under the Equality Act 2010 (EA) and, will be as set out in the table below: Number of items per month Establishment Payment 2,500 - 2,829 £23,278 2,830 - 3,149 £24,190 3,150+ £25,100 Number of items per month Practice Payment from 1 April 2020 to 30 September 2020 Contribution in Practice Payment to transition from 1 April 2020 to 30 September 2020 Contribution in Practice Payment for EA from 1 April 2020 to 30 September 2020 Up to 1,099 £300 £0 £300 1,100 - 1,599 £2,740 £0 £600 1,600 - 2,499 £3,828 £0 £750 2,500+ 32.9p per item 10.0p per item 6.6p per item 53 03/2022 Part VIA PAYMENT FOR ESSENTIAL SERVICES (PHARMACY CONTRACTORS) 2.4 Practice Payments from 1 January 2021 to 31 March 2021, which includes a contribution for provision of auxiliary aids for people eligible under the Equality Act 2010 (EA) and, will be as set out in the table below: 2.5 Practice Payments from 1 April 2021 to 31 December 2021, which includes a contribution for provision of auxiliary aids for people eligible under the Equality Act 2010 (EA) and, will be as set out in the table below: Number of items per month Practice Payment from 1 October 2020 to 31 December 2020 Contribution in Practice Payment to transition from 1 October 2020 to 31 December 2020 Contribution in Practice Payment for EA from 1 October 2020 to 31 December 2020 Up to 1,099 £150 £0 £150 1,100 - 1,599 £1,370 £0 £300 1,600 - 2,499 £1,914 £0 £375 2,500+ 49.5p per item 10.0p per item 6.6p per item Number of items per month Practice Payment from 1 January 2021 to 31 March 2021 Contribution in Practice Payment to transition from 1 January 2021 to 31 March 2021 Contribution in Practice Payment for EA from 1 January 2021 to 31 March 2021 Up to 1,099 £150 £0 £150 1,100 - 1,599 £1,370 £0 £300 1,600 - 2,499 £1,914 £0 £375 2,500+ 32.9p per item 10.0p per item 6.6p per item Number of items per month Practice Payment from 1 April to 31 December 2021 Contribution in Practice Payment to transition from 1 April 2021 to 31 December 2021 Contribution in Practice Payment for EA from 1 April 2021 to 31 December 2021 Up to 1,099 £450 £0 £450 1,100 - 1,599 £4,110 £0 £900 1,600 - 2,499 £5,742 £0 £1,125 2,500+ 32.9p per item 10.0p per item 6.6p per item 56 03/2022 Part VIA PAYMENT FOR ESSENTIAL SERVICES (PHARMACY CONTRACTORS) 4.8 With effect from 31 March 2018 all Pharmacy Contractors are required to be compliant with Phase 2 Releases 1, 2 & 3. From June 2019, compliance with phase 2, release 3 will be assessed against the percentage of ETC claim messages submitted for qualifying prescription items. Qualifying items are defined as those prescribed on a WP10 prescription containing a 2DRx barcode. In order to retain the IM&T allowance, each contractor must submit ETC claim messages to meet the following thresholds: Pharmacy contractors will be given at least three months’ notice of their pharmacy IT system’s capability to access each respective release of Phase 2. The following website shows the current status for each of the accredited systems/suppliers for Wales and status of all the Phase 2 Releases: http://howis.wales.nhs.uk/wmss. 4.9 From April 2021, the Microsoft 365 NHS Wales email service will be the only NHS Wales- compliant email service. To comply with Phase 2, release number 1, pharmacy contractors must ensure that the Microsoft 365 NHS Wales email service is adopted by 1 April 2021. 4.10 Appropriate arrangements must be in place to require a pharmacist or pharmacy technician to access their Microsoft 365 NHS Wales email daily, to deal appropriately and timeously with communications concerning patient safety from the Welsh Ministers, the Medicines and Healthcare products Regulatory Agency (MHRA) and NHS Wales communication issued via the NHS Wales Electronic National Alert Service (ENAS). 4.11 The arrangements required by 4.10 should detail the actions required by pharmacy staff to appropriately deal with all communications concerning patient safety, including keeping a record of actions undertaken to implement and/or comply with the communication. 'Appropriately' means that the Pharmacy Contractor has taken action to deal with the notice and Pharmacy Contractors are expected to meet the notice deadline in order to be considered to be acting in a 'timeously' manner, i.e. action is taken within the required timescale. 4.12 Pharmacy Contractors are required to inform the NHS-Shared Services Partnership- Contractor Services division whenever: 1) they commence connectivity to their individual premises, 2) have a change of system supplier, 3) have a change of accredited connectivity provider. This advice must be submitted using the ETP1 or ETP2 Claim Form, as appropriate. 4.13 A pharmacy contractor must submit the appropriately completed ETP Monthly Allowance Claim Form to NWIS not later than the last day of the first month that the premises can demonstrate that it is able to operate the services in Phase 2 Releases 1, 2 & 3. This will instigate receipt of the monthly allowance for that month and subsequent months. The monthly recurring payment is subject to the pharmacy premises’ ongoing compliance with the specified services and their terms. If at a later date a pharmacy premises becomes unable to comply with the requirements of this part they must as soon as is practicable notify their LHB and NWIS in writing of the date from which the pharmacy ceased to be compliant. The LHB Release Number Service/System Available Date Maximum Deployment Timescale 1 NHS Wales-compliant Email service (ENAS- Electronic NHS Alerts Service) 1 April 2010 30 September 2010 2 ETP - 2D-Barcoded Prescription service 30 September 2010 30 September 2011 3 Electronic Transmission of Claims service 30 April 2017 31 March 2018 Date Qualifying items in monthly account From 1 June 2019 40% From 1 September 2019 55% From 1 December 2019 70% From 1 March 2020 80% 57 03/2022 Part VIA PAYMENT FOR ESSENTIAL SERVICES (PHARMACY CONTRACTORS) may then determine whether payment of the recurring connectivity payment should be stopped on a permanent basis or suspended for a month (or period specified by the LHB). On resumption of the service, an updated ETP Monthly Allowance Claim Form should be submitted and connectivity and compliance to the services will have to be demonstrated by the pharmacy contractor. 4.14 LHBs may monitor and audit pharmacy contractor and individual premises compliance with the services in Phase 2 Releases 1, 2 & 3. Where NHS Wales audit and monitoring identify a pharmacy premises to be non compliant with the services in Phase 2 Releases 1, 2 & 3, and where that non compliance is within the control of the pharmacy contractor, action may result in the suspension of the recurring connectivity payment and NHS connectivity. 4.15 In 2007/08, to support the implementation requirements of Phase 2, an additional one-off payment of £1,000 was paid to all pharmacy contractors included, at that time, in a pharmaceutical list maintained by a LHB in Wales. The allocation applied only to pharmacy contractors included, at that time, in a pharmaceutical list maintained by a LHB. 4.16 Failure to place an order for respective Releases of a NHS Wales compliant system or service within three months following the maximum deployment date advised could result in the £1,000 allowance also being reclaimed. Further Information 4.17 These allowances and guidelines will be published in Part VIA of the Drug Tariff, the most recent edition of which can be found online at: http://www.nhsbsa.nhs.uk/ PrescriptionServices/4940.aspx 4.18 Further supplementary guidance on procedures to support the implementation of forthcoming developments will be provided, as appropriate. 5. Scheme to engage Community Pharmacy in a proportionate response to the emerging pandemic Influenza infection (Wales only) 5.1 Pharmacy Contractors in Wales who engage in the delivery of arrangements to enable the dispensing of antiviral medication from the national stockpile will receive the fee of £4 per item of this stock dispensed. No other fees or allowances will be payable for or in respect of items dispensed under this scheme. 5.2 This applies to stocks of antiviral medication delivered by LHBs to each community pharmacy across Wales in a pandemic situation namely: Oseltamivir (Tamiflu) all presentations Oseltamivir Oral solution (NHS manufactured special) 15mg in 1ml Zanamivir (Relenza) 5.3 Under the scheme GPs will write WP10 prescriptions for patients as outlined in the Chief Medical Officers letter dated 2 July 2009 and community pharmacists will dispense these prescriptions in accordance with the essential services element of their contract. 5.4 The prescriptions for this treatment will be processed in the usual way through the prescription pricing system. 5.5 The £4 per item of stock dispensed fee has been agreed in collaboration with Community Pharmacy Wales upon the principle that participation in the scheme should not afford the pharmacy contractor any loss of income nor should participation afford an opportunity to profit as a result of assisting in the delivery of services during a pandemic. 5.6 Fees and allowances as described above shall only be payable during an influenza pandemic and subject to notification of pharmacy contractors by the Welsh Government. 5.7 In situations other than an influenza pandemic, where a pharmacy contractor dispenses antiviral medication in accordance with the conditions described in Part XVIIIB, normal remuneration and reimbursement mechanisms shall apply. Pharmacy contractors should not normally dispense antiviral medication from the national stockpile other than in those circumstances described above. 5.8 This provision applies to prescriptions dispensed on or after 1 December 2010. 58 03/2022 Part VIA PAYMENT FOR ESSENTIAL SERVICES (PHARMACY CONTRACTORS) 6. Arrangements for patients shielding or self-isolating during Covid-19 (Wales only) 6.1 Community pharmacies in Wales that have arrangements in place for shielded patients and those who are self-isolating and who have no social network to continue to receive the medicines they need will receive a fee of 7.4p per item dispensed 6.2 The fee will be payable to all community pharmacies that, by the 5 June 2020 in respect of any community pharmacy that had such arrangements in place in April and/or May 2020 and subsequently by the 5th of the month immediately following the month in which the arrangements were in place, makes a declaration to the NHS Wales Shared Services Partnership confirming: • The GPhC Registration number of the pharmacist making the declaration; and • The approximate number of dispensed items provided by the pharmacy in the relevant month to patients who were shielding or self-isolating under the arrangements; 6.3 The fee in 6.1 is payable for prescriptions dispensed between 1 April 2020 and 31 March 2021. 7. Arrangements for distribution of Covid-19 Lateral Flow Test (LFT) kits by pharmacies (Wales only) 7.1 Community pharmacies in Wales that distribute Covid-19 LFT kits will receive a fee of £251.50+VAT following the first occasion they supply a LFT kit and a fee of £1.50+VAT for every LFT kit supplied thereafter. 7.2 Fees will be paid to community pharmacies that, by the 5th of the month immediately following the month in which the supplies were made, make a claim to the NHS Wales Shared Services Partnership using the National Electronic Claim and Audit Form (NECAF) system. 8. Transitional Payments (England only) 8.1 From 1 January 2022, pharmacy contractors who dispense 101 prescription items or more in any month will receive a monthly Transitional Payment which consists of two separate payments - a dispensing payment and a service payment as set out in Table 1. 8.2 For the pharmacy contractors to receive the monthly service payment of the transitional payment they must have: (i) claimed for at least one New Medicine Service (NMS) in the previous month; and (ii) been registered to provide the Community Pharmacy Consultation Service (CPCS) on the Manage Your Service (MYS) platform for greater than or equal to half of the number of full days in the previous month. Example 1 For a pharmacy contractor, who dispensed 2,000 prescription items in January 2022, to receive the service payment of £60 they must have claimed for one NMS undertaken in December by the 5 January 2022 and they must have been registered on MYS to provide CPCS for at least 16 days in December 2021. Example 2 For a pharmacy contractor, who dispensed 6,000 prescription items in March 2022, to receive the service payment of £882 they must have claimed for one NMS undertaken in February by the 5 March 2022 and they must have been registered on MYS to provide CPCS for at least 14 days in February 2022. 8.3 Contractors should note that the monthly amount of Transitional Payment may change over the course of the year. 61 03/2022 Part VIA PAYMENT FOR ESSENTIAL SERVICES (PHARMACY CONTRACTORS) 13. Reimbursement for PPE costs incurred within community pharmacy and dispensing appliance contractors (DACs) during the Covid-19 pandemic response (England only) Background 13.1 Community pharmacies continued to operate throughout the Covid-19 pandemic. Guidance was issued on 19 March 2020 to advise on operating model changes to reduce the risk of transmission https://generalpracticebulletin.cmail19.com/t/ViewEmail/d/ 42D38571E307F65F2540EF23F30FEDED/07BD036C356575E57EEA1DAE616D4B3C 13.2 In April 2020, Public Health England (PHE) guidance on PPE for community pharmacy recommended the sessional use of Type IIR fluid-resistant surgical face masks (FRSM) where pharmacy staff are unable to maintain social distancing of 2 metres from patients (with possible or confirmed Covid-19). 13.3 Community pharmacies were invited to sign-up to the PPE portal from 3 August 2020 as an emergency supply route and then for all Covid-19 PPE requirements from 21 September 2020. Claims process 13.4 Claims must be submitted through the MYS portal (with the exception of central claims made for pharmacies with six or more branches), for PPE purchased between 27 February 2020 and 31 December 2020 for use in the delivery of NHS pharmaceutical services up to 31 March 2021, as a result of Covid-19 infection control guidance. All claims must be submitted by 12 February 2021. 13.5 Pharmacies with six or more branches may make a single central claim that must be submitted by email to nhsbsa.pharmacysupport@nhs.net. However, this must be supported by appropriate evidence, using the assigned spreadsheet to show what PPE was sent to each branch together with a cumulative total. This is being allowed on an exceptional basis because this claiming process is being implemented retrospectively. Had pharmacies known about this claims process at the time they may have established their accounting systems differently. 13.6 The items that can be claimed are aprons, gloves, Type IIR masks and hand sanitiser. Between 27 February 2020 and 30 June 2020 any protective equipment used in substitution of unavailable items can be covered under standard claims. This includes visors. Where the standard claims amount does not cover the costs for standard protection, an exceptional claim should be made. 13.7 Each pharmacy will be able to make claims under two categories: - standard claims – set at a banded rate to cover standard PPE use from 27 February 2020 to 31 October 2020. However, this would not apply to pharmacies that were open for less than 90% of the time period, or that changed ownership during this time. - exceptional claims – to cover any PPE purchased between 27 February 2020 and 31 October 2020 in excess of the standard claim value and to be used up to 31 March 2021 and/or any PPE purchased from 1 November 2020 to 31 December 2020 and to be used up to 31 March 2021. Any pharmacies that were open for less than 90% of the time period from 27 February 2020 to 31 October 2020 or that changed ownership during this time period will also need to claim their actual costs via the exceptional claim route. 13.8 Distance selling pharmacies and dispensing appliance contractors will be eligible to claim the standard payment based on their dispensing volumes in the same way as bricks and mortar pharmacies. They will also be eligible to make an exceptional claim. Standard claim criteria 13.9 Standard claims must meet the following criteria: a They must relate to costs incurred between 27 February 2020 and 31 October 2020; b They must require the contractor to declare that - (i) their claim relates to PPE purchased for use in delivery of NHS pharmaceutical services and in accordance with PHE guidance, (ii) they were open for at least 90% of the period in question (under their current ODS code), and 62 03/2022 Part VIA PAYMENT FOR ESSENTIAL SERVICES (PHARMACY CONTRACTORS) (iii) whether they opened for more than 60 hours per week on average over the period; and c They will be paid at the claim amounts per Table 1. These amounts allow for: (i) Sessional use of masks for dispensing plus an allowance for clinical services, excluding flu vaccinations (covered under sessional use) at £30 per box of 50 masks (£0.60 per mask), and (ii) One box of gloves per month for all pharmacies, one roll of aprons for February – October and hand hygiene for February – October. Table 1. Standard claim bands Exceptional claims criteria 13.10 Exceptional claims must meet the following criteria: a they must relate to expenditure incurred during the period from 27 February 2020 to 31 October 2020 only where expenditure is in excess of the standard claim value or where the contractor has not been open for the requisite 90% of the period or has changed ownership; b they must be for expenditure with an invoice date up to and including 31 December 2020 and for PPE to be used up to 31 March 2021; c where they relate to expenditure incurred from 1 November 2020 to 31 December 2020, the contractor will be required to declare that they did not receive duplicative PPE from the portal during the same period; d contractors must confirm that they have documentation to evidence the value of their combined standard and exceptional claims and can make this documentation available on request; and e where they relate to PPE that is outside the standard list (aprons, gloves, Type IIR masks and hand sanitiser) the contractor must be able to evidence the need for that PPE if requested to do so. This evidence may take the form of a staff risk assessment or similar. 13.11 We intend to review the exceptional claims prior to payment on a sample/risk basis including checks of proof of purchase documentation, and, by exception, a clinical review of the appropriateness of the claim. Additional Information 13.12 Where contractors have monthly dispensing volumes that apply to multiple claim bands, the mode average will be used to calculate payment. Where there are two modes, the higher claim band will be used. 13.13 Contractors whose exceptional claims were wholly or partly rejected may request a review of the payment by the Department of Health and Social Care. A contractor may request a review if: • they wish to question how the criteria in paragraphs 13.10 or 13.11 were applied. • in their view an error was made in the handling of their claim. Band Number of items per month Standard claim, <=60 opening hours Standard claim, >60 opening hours 1 0 100 £830 £1,650 2 101 2,500 £830 £1,650 3 2,501 5,000 £1,030 £1,850 4 5,001 12,500 £1,640 £2,460 5 12,501 19,167 £2,490 £3,310 6 19,168 £3,240 £4,060 63 03/2022 Part VIA PAYMENT FOR ESSENTIAL SERVICES (PHARMACY CONTRACTORS) The Department of Health and Social Care will have access to the evidence previously supplied to the NHSBSA to support the exceptional claims criteria above. If available, contractors may also supply additional information to support their claim. Please note however, that new or increased claims will not be accepted. Contractors may be contacted directly by a DHSC or NHSBSA official to discuss their claim in person and if the contractor wishes, a PSNC representative or official may also be asked to participate in the discussions. All requests for review must be submitted to nhsbsa.pharmacysupport@nhs.net by no later than 30 September 2021 and should include ‘PPE’ in the email subject. 14. NHS Discharge Medicine Service (England only) 14.1 Pharmacy contractors will receive an upfront payment of £400 to support initial costs incurred in setting up the NHS Discharge Medicine Service (DMS) (including the development of Standard Operating Procedures and training and assessment of competence). Any pharmacy on the pharmaceutical list on 1 February 2021 will automatically receive this payment on 1 April 2021, and this payment will be itemised in the Schedule of Payments. Any new pharmacies opening after 1 February 2021 but before the end of the 2021/22 financial year (this excludes contractors changing ownership, merging or relocating) will automatically be itemised in the next applicable Schedule of Payments. 14.2 From 15 February 2021 pharmacy contractors will receive a fee of £35 for each completed NHS DMS (i.e. stages 1 to 3 have been completed as set out in paragraph 14.3 below). The payment must be claimed via the Manage Your Service (MYS) portal no later than the 5th day of the month following that in which the NHS DMS was completed. That claim must be made by somebody who is or is acting under the responsibility of a registered pharmacist or pharmacy technician, who is responsible for maintaining the confidentiality of any personal data concerning health that is submitted as part of the claim. 14.3 On the rare occasion (see paragraph 14.4) that a pharmacy contractor might not be able to complete the NHS DMS in full, the contractor will be able to claim the following fees for the stages of the NHS DMS that have been completed (n.b. details on the action required by pharmacy contractors at each stage of the NHS DMS are provided in Chapter 8 of Guidance on the NHS (Charges and Pharmaceutical and Local Pharmaceutical Services) (Amendment) Regulations 2020): • Stage 1 - £12 • Stage 2 - £11 • Stage 3 - £12 14.4 The claim for the stages of the DMS completed by the contractor must be made via the MYS portal no later than the 5th day of the month following that in which the final stage that the contractor was able to undertake was completed. Where a contractor has completed some of the stages of the NHS DMS, but not all the stages of the NHS DMS that they intend to complete, they should not yet make a claim. When a contractor does claim payment for all of the stages they provided, but not for a completed DMS referral, as part of the claim the contractor must provide one of the following reasons as to why the NHS DMS service was not provided in full to the patient. A claim for part completion of the NHS DMS may only be made where one of the reasons set out below applies: • Patient uncontactable or withdraws consent following completion of Stage 1: Where stage 1 of the service has been delivered but the patient withdraws consent to receive the service or the first prescription post-discharge is not received by the community pharmacy to complete stage 2 of the service and no contact is made by the patient, reasonable attempts must be made by the community pharmacy to contact the patient using the contact details set out in the referral. In this scenario, it is also possible that the patient has been re-admitted to hospital, has been admitted to a care home or has died. Where the community pharmacy is unable to reach the patient (or the patient has been readmitted to hospital or admitted to a care home) the community pharmacy should share any findings of concern from stage 1 of the service with the patient’s general practice before claiming payment for all of the stages they provided. 66 03/2022 Part VIA PAYMENT FOR ESSENTIAL SERVICES (PHARMACY CONTRACTORS) 15.8 Each claim must - (a) Confirm that it is for Covid-19 related costs in the four categories in table 1, incurred between 1 March 2020 and 31 March 2021 for the delivery of NHS pharmaceutical services. (b) Specify the amount claimed in each category of costs (categories 1 to 3) and the evidence available to support the claim. (c) Confirm that the documentation to evidence the value of the claim will be made available to the NHSBSA on request within 5 working days upon receiving a request from the NHSBSA. (d) Where a claim is made for closures agreed by NHSE&I, confirm that the closure was agreed with NHSE&I, the period of the closure, the number of days the pharmacy was closed and the name of the NHS authority that was notified of the closure. If confirmed by NHSE&I that the closure was notified and is in scope, contractors will be paid their average daily fees in 2019/20 plus their average daily number of dispensed items in 2019/20 multiplied by £0.77 to reflect medicine margin for each day they were closed between 1 March 2020 and 31 March 2021 for a maximum of 14 days. (e) Be submitted by 15 August 2021. 15.9 Claims that do not meet the criteria set out in paragraph 15.8 will be rejected. 15.10 Claims will be reviewed before or following payment. Where the evidence submitted does not support the claim, the payment will either be reduced before it is made to the contractor or, if payment has taken place, the over-payment will be recovered from the contractor’s next monthly payment. If a contractor does not agree with the reduction of their payment and the recovery of the difference between the amount claimed and the amount paid, then they should contact the NHSBSA to make representations as to why they think their payment should not have been reduced. This appeal process will be open until 1 November 2022, and will be determined as quickly as the circumstances allow. All appeals will be considered by the Secretary of State. Claims reviewed before payment in full will be made will include: (a) Claims exceeding one third of annual NHS income in 2020/21 for contractors who opened after March 2019 or an average of 2019/20 and 2020/21 income for contractors who opened before March 2019; (b) Claims where initial review identifies a risk of a potential error that could result in a significant overpayment. Partial payment to contractors whose claims fall under categories 15.10 a and 15.10b will be made to ensure the recovery of Covid-19 advance during the verification of these claims does not unreasonably affect contractor’s cashflow. 15.11 Contractors will not automatically receive the amount they have claimed. Once the total number of claims is in, HM Treasury will be asked to determine the funding envelope for the claims. If the envelope is the same as the amount claimed, the claims will be paid in full. If some form of capping mechanism proves necessary, then this will be set out in a Drug Tariff determination that will be published in September. 4 Notified closures for infection control purposes (maximum 14 days) - Notified closures for infection control purposes where all staff had to self-isolate - Notified closures for infection control purposes of pharmacies in health centres - Closures not notified to NHSE&I - Closures not for the purpose of infections control - Closures for business reasons - Closures exceeding 14 days Contractors are asked to specify the dates and number of days the pharmacy closed following notification of NHSE&I. Following confirmation from NHSE&I that the contractor notified the closure and that the closure is in scope, contractors will be paid according to paragraph 15.8d. 67 03/2022 Part VIB PAYMENT FOR ESSENTIAL SERVICES (APPLIANCE CONTRACTORS) Part VIB - Payment for Essential Services (Appliance Contractors) 1. Infrastructure Payments 1.1 Appliance contractors who dispense a stated number of prescription items in any month will receive an Infrastructure Payment from 1 April 2010. 1.2 Except where paragraph 1.4 applies the level of infrastructure payment will be as follows: • within the first band, all Appliance Contractors will receive a fixed monthly payment of £150.00; and • in the remaining bands, Appliance Contractors will be paid a fee per each Part IXA, Part IXB and Part IXC item dispensed in that month 1.3 Infrastructure payment does not have to be claimed but will be paid automatically each month. 1.4 Appliance contractors who have been added to the pharmaceutical list following a successful application which was granted after 1 July 2010 on the basis of the exemptions set out in regulation 13 of the NHS (Pharmaceutical Services) Regulations 2005 will not receive any infrastructure payment if they dispense less than 2,240 items in any month. If they dispense 2,240 items or more, they will receive £2.40 per item for items dispensed between 2,240- 35,000 and £2.30 per item for items dispensed above 35,000. Similar applications are not possible under the NHS (Pharmaceutical Services) Regulations 2012. 2. Electronic Transmission of Prescriptions Allowances 2.1 The Electronic Prescription Service will be deployed in phases with two releases (Release 1 and Release 2) of ETP compliant pharmacy systems. Further details of service implementation and deployment can be found at http://www.digital.nhs.uk. 2.2 In order to be able to use the Electronic Prescription Service appliance contractors will need to have: • an ETP compliant dispensing system accredited as such by NHS Digital (either Release 1 or Release 2) • appropriate network connectivity to be able to operate the Electronic Prescription Service (details of connectivity arrangements for appliance contractors will be made available by NHS Digital) • staff operating the service who are registered users and have been issued with smart cards and PIN numbers under the NHSCB’s registration authority arrangements. 2.3 The release 1 allowance is paid only once, in relation to pharmaceutical services provided at the same premises irrespective of any subsequent merger or sale; or where there has been a relocation, there is no right to claim a further Release 1 allowance for the new relocated premises 2.4 A further allowance of £1,000 will be paid linked to the appliance contractor deploying Release 2 of the Electronic Prescription Service. Payment will be automatically triggered, when an appliance contractor submits a synthetic reimbursement endorsement message to NHS Prescription Services. This synthetic reimbursement endorsement message must be submitted to NHS Prescription Services by a date yet to be determined of which three months notice will be given, in order for the allowance to be paid. Band identifier Number of Part IX prescription items dispensed in one month Infrastructure payment A 1 - 10 £150.00 fixed B 11 - 1,000 £13.60 per item C 1,001 - 35,000 £2.40 per item D 35,000 + £2.30 per item 68 03/2022 Part VIB PAYMENT FOR ESSENTIAL SERVICES (APPLIANCE CONTRACTORS) 2.5 The Release 2 allowance is paid only once, in relation to pharmaceutical services provided at the same premises irrespective of any subsequent merger or sale; or where there has been a relocation, there is no right to claim further Release 2 allowance for the new relocated premises. 2.6 Subject to the conditions in 2.2, an appliance contractor who operates Release 1 or Release 2 of the service if an appropriate prescription is presented or requested, shall be entitled to an ETP monthly allowance of £200 per calendar month from the NHSCB for each month that he is able to operate the service. 2.7 A contractor must submit an ETP Monthly Allowance Claim Form (previously known as form PPAETP1) to the NHSCB by the end of the first month that he is able to operate the service to receive the monthly allowance for that month and subsequent months. If at a later date the appliance contractor becomes unable to operate the Electronic Prescription Service, the contractor must inform the NHSCB in writing immediately so that the NHSCB can determine whether payment of the ETP monthly allowance should be stopped on a permanent basis or suspended for a month (or other period as specified by the NHSCB). When the EPS service is resumed, a completed ETP Monthly Allowance Claim Form will need to be resubmitted. 3. Electronic Transfer of Prescriptions (Wales) 3.1 The Electronic Transfer of Prescription (ETP) service for Wales will be deployed in phases with two separate releases (Release 1, 2D Barcoded Prescriptions and Release 2, Electronic Transmission of Claims) of ETP compliant pharmacy systems. Further details of service implementation and deployment can be found at http://howis.wales.nhs.uk/wmss. 3.2 In order to be able to use the full Electronic Transfer of Prescription service, Dispensing Appliance Contractors will need to have: • an ETP compliant dispensing system, accredited as such by the NHS Wales (firstly Release 1 and then Release 2) • appropriate NHS Wales accredited network connectivity (details of which will be made available to Dispensing Appliance Contractors by NHS Wales), to be able to operate the full Electronic Transfer of Prescription service (specifically Release 2) • designated staff to operate the service who are registered users and have been notified to NHS Wales authorities. 3.3 Any Dispensing Appliance Contractors who have dispensed more than 1200 items in the 12 months preceding 1 April 2010 will be paid an allowance of £2,600 in their June 2010 payment. Payment will automatically be triggered and no claim form needs to be submitted. If an Appliance Contractor dispenses less than 1200 items in the 12 months before 1 April 2010 or they open after 1 April 2010, if they are in a position to operate Release 1 of the Electronic Transfer of Prescription service, they may claim the allowance of £2,600 by submitting an ETP3 Claim Form to the NHS Wales Business Services Centre. Claims must be made by 31 March 2011. After this date no further payments will be made in respect of Release 1. 3.4 The Release 1 allowance is paid only once, in relation to pharmaceutical services provided at the same premises irrespective of any subsequent merger or sale; or where there has been relocation, there is no right to claim a further Release 1 allowance for the new relocated Premises. 3.5 A further allowance of £1,000 will be paid linked to the Dispensing Appliance Contractor deploying Release 2 of the Electronic Transfer of Prescription service. Payment will be automatically triggered, when a Dispensing Appliance Contractor submits a synthetic reimbursement endorsement message to NHS Wales Prescription Services Unit. This synthetic reimbursement endorsement message must be submitted to NHS Wales Prescription Services Unit by a date yet to be determined of which three months’ notice will be given, in order for the allowance to be paid. 3.6 The Release 2 allowance is paid only once, in relation to pharmaceutical services provided at the same premises irrespective of any subsequent merger or sale; or where there has been a relocation, there is no right to claim further Release 2 allowance for the new relocated premises. 71 03/2022 Part VIC ADVANCED SERVICES (PHARMACY AND APPLIANCE CONTRACTORS)(ENGLAND) Stoma Customisation 8. In England, from 1 April 2010 a fee of £4.32 is payable for every Part IXC prescription item that can be customised1. The fee does not have to be claimed and will be paid automatically to those pharmacy and appliance contractors who in England have informed the NHSBSA of their intention to provide stoma appliance customisation services as an advanced service by the end of the month before they start providing the service. 9. Contractors are however required to meet certain preconditions, set out below in direction 9 of the principal Directions, before the NHSCB is able to enter into arrangements with them to provide the service - and their ongoing entitlement to provide the service is subject to compliance with the conditions that the NHSCB is required to impose on them by virtue of direction 10 of the principal Directions. 1Products that qualify for the stoma customisation fee have been annotated in the Drug Tariff. Appliance Use Review 10. In England, from 1 April 2010 a fee is payable to all pharmacy and appliance contractors meeting the requirements for this service for each Appliance Use Review they have carried out. The requirements they have to meet are also set out below in directions 11 to 13 of the principal Directions. As with the stoma customisation, there are both preconditions that the contractor has to meet before the NHSCB is able to enter into arrangements with them (set out in direction 11 of the principal Directions), and ongoing entitlement to provide the service is subject to compliance with the conditions that the NHSCB is required to impose on them (see directions 12 and 13 of the principal Directions) 11. A fee of £28 is payable for an Appliance Use Review conducted at premises or by telephone or video link managed by the pharmacy or appliance contractor. A fee of £54 is payable for a review conducted at the user’s home. If, within a 24 hour period, reviews are conducted for several users living at the same location, the appliance or pharmacy contractor may claim £54 for the first review and £28 for each subsequent review. 12. In England, the total number of Appliance Use Reviews that an appliance or pharmacy contractor may claim fees for will be limited to one for every 35 Part IXA (qualifying items), Part IXB and Part IXC prescription items dispensed for the period commencing on 1 April and ending on 31 March in any one year (see direction 13 of the principal Directions). 13. In England contractors will be paid monthly, via the Pricing Authority on receipt of the appropriate claim form in the relevant month. Table 1 Volume of prescription items per month Number of full service interventions per month necessary to achieve each target Maximum number of full service interventions per month for which payment will be received 10% target £25 per full service intervention 20% target £26 per full service intervention 30% target £27 per full service intervention 40% target £28 per full service intervention 50% target £28 per full service intervention 60% target £28 per full service intervention 70% target £28 per full service intervention 80% target £28 per full service intervention 90% target £28 per full service intervention 0-1500 1 2 3 4 5 6 7 8 9 10 1501-2500 2-3 4-5 6-7 8-9 10-11 12-13 14-15 16-17 18-19 20 2501-3500 3-5 6-8 9-11 12-14 15-17 18-20 21-23 24-26 27-29 30 3501-4500 4-7 8-11 12-15 16-19 20-23 24-27 28-31 32-35 36-39 40 4501-5500 5-9 10-14 15-19 20-24 25-29 30-34 35-39 40-44 45-49 50 5501-6500 6-11 12-17 18-23 24-29 30-35 36-41 42-47 48-53 54-59 60 6501-7500 7-13 14-20 21-27 28-34 35-41 42-48 49-55 56-62 63-69 70 7501-8500 8-15 16-23 24-31 32-39 40-47 48-55 56-63 64-71 72-79 80 8501-9500 9-17 18-26 27-35 36-44 45-53 54-62 63-71 72-80 81-89 90 9501-10500 10-19 20-29 30-39 40-49 50-59 60-69 70-79 80-89 90-99 100 +1000 (+1)-(+2) (+2)-(+3) (+3)-(+4) (+4)-(+5) (+5)-(+6) (+6)-(+7) (+7)-(+8) (+8)-(+9) (+9)-(+10) (+10) 72 03/2022 Part VIC ADVANCED SERVICES (PHARMACY AND APPLIANCE CONTRACTORS)(ENGLAND) Community Pharmacy Seasonal Influenza Vaccination Advanced Service 14. From 1 September 2021 a fee of £9.58 will be paid for each adult flu vaccination administered by a pharmacy contractor. This payment includes a contribution to cover training and clinical waste costs associated with the vaccination. 15. Pharmacy contractors will be reimbursed the cost of the vaccine in accordance with Part II, Clause 8C (Basic Price) of the Drug Tariff. An allowance at the applicable VAT rate will also be paid. 16. The fees will be payable only to contractors meeting the requirements of the service. These are set out in directions 7A and 7B of the principal Directions and the service specification. 17. Claims for payments for this programme should be made monthly, via the Manage Your Service platform provided by the NHSBSA. Claims will be accepted by the NHSBSA within six months of administration of the vaccination or by 31 August 2022, whichever date is earlier. Later claims will not be processed. Payments to contractors will be made monthly as part of their normal payment schedule. Information on submitting a claim is available via the NHSBSA website (https:// www.nhsbsa.nhs.uk/pharmacies-gp-practices-and-appliance-contractors/dispensing-contractors- information/community-1). When using the Manage Your Service platform provided by the NHSBSA for submitting claims, contractors should ensure that they only make a single claim for each calendar month, as subsequent submissions for that claim month will not be accepted by the Manage Your Service platform. Claims associated with offsite provision of the Community Pharmacy Seasonal Influenza Vaccination Advanced Service 18. From the 1 September 2021, subject to the payment conditions set out in paragraphs 19 and 20, pharmacy contractors will be remunerated a contribution towards the costs deemed reasonable by NHS England and NHS Improvement (NHSE&I) to deliver adult flu vaccinations from offsite premises. 19. The conditions referred to above for claiming additional reasonable costs are: (i) pre-authorisation of costs is approved by the contractor’s regional NHSE&I team prior to any spend and in line with the 2021-22 Autumn and Winter Financial and Payments Guidance for NHS Regional Teams for the Covid-19 Vaccination Programme and the Advanced Flu Service (Community Pharmacies). (ii) that the costs are not already covered via any other means. 20. In relation to the authorisation of venue hire, authorisation of costs will be given by regional NHSE&I teams on a first come, first served basis, from a finite budget. NHSE&I will only authorise where: • there is no other venue that has already been paid for either very near or at the same place, at the same time, that the contractor could make use of, and it is not possible to use existing estates or premises to deliver vaccination clinics, or to use NHS void and vacant space brokered through the contractor’s regional NHSE&I team. • the session is not deemed by NHSE&I to create overprovision in a certain area or at a certain time, to ensure provision of offsite vaccinations are evenly spread, • in the contractor’s professional opinion, the venue is suitable for the provision of pharmaceutical services and the contractor is satisfied that it can meet General Pharmaceutical Council standards and Infection Prevention and Control guidance, • the contractor has enough vaccine supplies to run the offsite clinic and vaccinate expected attendees. 21. Claims for payments for this programme should be made monthly, via the webform on the Manage Your Service platform provided by the NHSBSA and available at https://services.nhsbsa.nhs.uk/ nhs-prescription-services-submissions/login. Claims will be accepted by the NHSBSA within six months of the hire of the venue or by 31 August 2022, whichever date is earlier. Each claim must include the amount being claimed towards unavoidable costs, the reference number(s) from the relevant NHSE&I regional team approving the costs and a declaration that the contractor has met the cost and that they can provide evidence to support the claim if requested by NHSBSA. Payment will be made via the NHSBSA schedule once approved. 73 03/2022 Part VIC ADVANCED SERVICES (PHARMACY AND APPLIANCE CONTRACTORS)(ENGLAND) NHS Community Pharmacist Consultation Service (CPCS) 22. In England, from 29 October 2019, the following fee will be paid for the provision of the NHS Community Pharmacist Consultation Advanced Service (CPCS). Regardless of whether a medicine/appliance was supplied, a fee of £14.00 will be paid in respect of each referral received and completed by the pharmacy contractor via the NHS 111, IUC CAS or General Practice referral route into CPCS as part of the Advanced Service 23. Other referrals via NHS 111, IUC CAS or General Practice and requests by patients for emergency supplies that are not part of the Advanced Service, do not attract this fee. 24. No further fees will be paid for the CPCS where an urgent medicine is supplied, and any items dispensed will not contribute to the establishment payment and deduction scale calculations. 25. Pharmacy contractors will be reimbursed* the cost of any supplied medicine/appliance following a referral for urgent medicines/appliances supply in accordance with Part II, Clause 8 (Basic Price) of the Drug Tariff. An allowance at the applicable VAT rate will also be paid, where applicable. 26. The fee mentioned in paragraph 22 will be payable only to contractors who have registered for the CPCS scheme and who meet the requirements of the service. The registration for the CPCS scheme will be via the NHSBSA Manage Your Service (MYS) portal. 27. The service requirements are set out in directions 7BA and 7BB of the principal Directions and the NHSCB service specification. Whether or not a referral has been completed is to be understood by reference to the service specification. 28. Claims for payments for this service and for reimbursement of costs for items supplied for urgent medicines/appliances supply should be made monthly, via the Manage Your Service platform provided by the NHSBSA and/or the CPCS Pharmacy IT system (where this functionality is available). Claims will be accepted by the NHSBSA within six months of completion of a referral, in accordance with the usual Drug Tariff claims process. Later claims will not be processed. 29. The NHSBSA will make appropriate payments claimed by the pharmacy contractor as described above, in the same payment month as other payments for NHS Pharmaceutical Services and the payments will be separately itemised on the FP34 Schedule of Payments. 30. Where urgent medicines/appliances are supplied, and the patient is exempt from payment of NHS prescription charges, the pharmacy contractor must complete an FP10DT EPS dispensing token with the information required in the NHSCB service specification and ensure completion of the exemption declaration in line with paragraph 2 of Part XVI of the Drug Tariff. These completed FP10DT EPS dispensing tokens should be sent to the NHSBSA as part of the month-end submission (clearly separated within the batch and marked ‘CPCS’), which should be sent not later than the 5th day of the month following that in which the urgent supply was made*. *Subject to the contractor having submitted a claim via the Manage Your Service platform containing all of the required information, the cost of medicines or appliances supplied under this part of the service will be reimbursed using the basic price specified in Drug Tariff Part II Clause 8 (Basic Price). For clarity, no other elements of the Drug Tariff in relation to reimbursement of medicines or appliances apply to this service, including the payments for consumables and containers Claims associated with initial local engagement in preparation for delivering the GP referral pathway of the CPCS 31. From 1 November 2020, subject to the payment conditions set out in paragraph 32, pharmacy contractors will be remunerated a contribution of £300 towards the costs associated with initial engagement with local partners in preparation for delivering the GP referral pathway of the CPCS. 32. The conditions referred to above for claiming the payment for costs associated with initial local engagement, with Primary Care Networks (PCNs), GPs etc., in preparation for delivering the GP referral pathway of the CPCS Advanced Service are that contractors must: • complete the activity described at Annex F of the service specification by 30 June 2021, and • be able to produce the required documentation, if requested to do so by the NHSCB or the NHSBSA, so that it can be evidenced at a later date. Further details can be found in Annex F of the service specification. 76 03/2022 Part VIC ADVANCED SERVICES (PHARMACY AND APPLIANCE CONTRACTORS)(ENGLAND) D I R E C T I O N S THE NATIONAL HEALTH SERVICE ACT 2006 The Pharmaceutical Services (Advanced and Enhanced Services) (England) Directions 2013 The Secretary of State gives the following Directions in exercise of the powers conferred by sections 127, 128, 272(7) and (8) and 273(1) of the National Health Service Act 2006(a). CONTENTS PART 1 Introductory 1. Citation, commencement and application 2. Interpretation 3. Revocations PART 2 Advanced services: pharmacy contractors only 4. MUR services: general matters and pre-conditions for making arrangements 5. MUR services: ongoing conditions of arrangements 6. New Medicine Service: general matters and preconditions for making arrangements 7. New Medicine Service: ongoing conditions of arrangements 8. Duration of New Medicine Service PART 3 Advanced services: appliances 9. Establishing and maintaining stoma appliance customisation services 10. Requirements applying to stoma appliance customisation services 11. Establishing and maintaining appliance use review services for specified appliances 12. Requirements applying to appliance use review services 13. Maximum number of appliance use review services eligible for payment PART 4 Enhanced services: pharmacy contractors only (a) 2006 c. 41. Section 128 has been amended by the Health and Social Care Act 2012 (c. 7) (“the 2012 Act”), Schedule 4, paragraph 64; and section 128 has been amended by the 2012 Act, Schedule 4, paragraph 65. 77 03/2022 Part VIC ADVANCED SERVICES (PHARMACY AND APPLIANCE CONTRACTORS)(ENGLAND) 14. Enhanced services provided by pharmacy contractors SCHEDULE 1 — National Target Groups for MUR services SCHEDULE 2 — NMS medicines PART 1 Introductory Citation, commencement and application 1.—(1) These Directions may be cited as the Pharmaceutical Services (Advanced and Enhanced Services) (England) Directions 2013 and come into force on 1st April 2013. (2) These Directions apply in relation to England. Interpretation 2. In these Directions— “the 2012 Directions” means the Pharmaceutical Services (Advanced and Enhanced Services) (England) Directions 2012(a), as in force on 31st March 2013; “the Act” means the National Health Service Act 2006; “appliance contractor” means a person included in a list prepared under regulation 10(2)(b) of the Pharmaceutical Services Regulations (pharmaceutical lists and EPS lists); “AUR service” is to be construed in accordance with direction 11(1); “BNF” means the current edition of British National Formulary, which is published jointly by the Royal Pharmaceutical Society and the British Medical Association(b); “clinical management plan” has the same meaning as in the Human Medicines Regulations 2012(c); “Drug Tariff” has the meaning given in regulation 89(1) of the Pharmaceutical Services Regulations (the Drug Tariff and section 164: general provisions); “drugs” includes medicines; “financial year” means the period of 12 months ending on 31st March in any year; “general practitioner”, in relation to a patient, means any medical practitioner who is, or who is a member of, a provider of primary medical services that holds the registered patient list on which the patient is a registered patient; “gluten free foods” means only those gluten free foods that are listed in Part XV of the Drug Tariff (borderline substances); “high risk medicine” has the meaning given in paragraph 1 of Schedule 1; “health care professional” means a person, other than a social worker, who is a member of a profession regulated by a body mentioned in section 25(3) of the National Health Service Reform and Health Care Professions Act 2002(d) (the Council for Healthcare Regulatory Excellence); (a) Signed on 20th July 2012. (b) The Formulary is available at www.bnf.org. (c) S.I. 2012/1916. (d) 2002 c.17. Subsection (3) has been amended by the Health and Social Care Act 2008 (c. 14), section 113(2) and Schedule 10, paragraph 17, and by S.I. 2010/231. The Council’s name was changed to the Council for Healthcare Regulatory Excellence by section 113(1) of the Health and Social Care Act 2008. 78 03/2022 Part VIC ADVANCED SERVICES (PHARMACY AND APPLIANCE CONTRACTORS)(ENGLAND) “listed chemist premises” has the same meaning as in the Pharmaceutical Services Regulations; “New Medicine Service” is to be construed in accordance with direction 6(1) and (2); “MUR certificate” means a statement of satisfactory performance certificate awarded or endorsed by a higher education institute being evidence that a person has satisfactorily completed an assessment relating to the competency framework for registered pharmacists providing MUR services approved by the NHSCB (or, pending the first such approval by the NHSCB, by the Secretary of State(a)); “MUR services” is to be construed in accordance with direction 4(1); “NHS BSA” means the NHS Business Services Authority established by the NHS Business Services Authority (Awdurdod Gwasanaethau Busnes y GIG) (Establishment and Constitution) Order 2005(b); “NHSCB” means the National Health Service Commissioning Board; “NMS medicine” has the meaning given in paragraph 1 of Schedule 2; “out of hours period” means, in relation to pharmacy premises, the periods of time that are not part of the hours during which the pharmacy premises must be open by virtue of paragraph 23(1) of Schedule 4 to the Pharmaceutical Services Regulations(c) (terms of service of NHS pharmacists – pharmacy opening hours: general) (these hours are referred to in those Regulations as core opening hours); “the Pharmaceutical Services Regulations” means the National Health Service (Pharmaceutical and Local Pharmaceutical Services) Regulations 2013(d); “pharmacist independent prescriber” has the same meaning as in the Pharmaceutical Services Regulations; “pharmacy contractor” means a person included in a list prepared under regulation 10(2)(a) of the Pharmaceutical Services Regulations; “pharmacy premises” has the same meaning as in the Pharmaceutical Services Regulations; “registered patient” means a patient who is included in a list that is a registered patient list for the purposes of the Primary Medical Services (Sale of Goodwill and Restrictions on Sub- contracting) Regulations 2004(e); “relevant Primary Care Trust”, in relation to a period before 1st April 2013, means the Primary Care Trust that entered into the arrangements with the contractor that are continuing, pursuant to these Directions, with the NHSCB (where such arrangements are continuing by virtue of a transfer scheme); “specialist nurse” means a person who is— (a) registered in the Nurses’ Part or Specialist Community Public Health Nurses’ Part of the register maintained by the Nursing and Midwifery Council under article 5 of the Nursing and Midwifery Order 2001(f) (establishment and maintenance of register); and (b) employed or engaged by any pharmacy contractor or appliance contractor for the purposes of conducting a review of a person’s use of specified appliances; “specified appliance” means— (a) any of the following appliances listed in Part IXA of the Drug Tariff— (i) a catheter appliance (including a catheter accessory and maintenance solution), (ii) a laryngectomy or tracheostomy appliance, (a) The competency framework in place on 1st April 2013 is the one published by the Department of Health on its website, www.dh.gov.uk. (b) S.I. 2005/2414. (c) Paragraph 22 has been amended by S.I. 2006/3373 and 2009/2205. (d) S.I. 2013/349. (e) S.I. 2004/906; see regulation 2(2) of those Regulations. (f) S.I. 2002/253. 81 03/2022 Part VIC ADVANCED SERVICES (PHARMACY AND APPLIANCE CONTRACTORS)(ENGLAND) (6) A registered pharmacist who is, or who is employed or engaged by, P may provide MUR services other than at an acceptable location if that registered pharmacist does so— (a) by telephone to a particular patient on a particular occasion; and (b) in circumstances where the telephone conversation cannot be overheard (except by someone whom the patient wants to hear the conversation, for example a carer), but only if P has obtained the approval of the NHSCB to do so on that particular occasion. MUR services: ongoing conditions of arrangements 5.—(1) The NHSCB must ensure that arrangements pursuant to direction 4(1) with a pharmacy contractor (P) provide that— (a) only a registered pharmacist with an MUR certificate, a copy of which has been supplied to the NHSCB (or before 1st April 2013 the relevant Primary Care Trust), may perform MUR services; (b) MUR services are only provided— (i) at an acceptable location within the meaning given in direction 4(5), excepted in the circumstances provided for in direction 4(6), and (ii) at a location for which the NHSCB’s approval is required by virtue of direction 4(5)(b) or (c), if the necessary approval has been given by the NHSCB (or, in the case of approvals under direction 4(5)(b) or (c)(ii), before 1st April 2013 by the relevant Primary Care Trust) and has not been withdrawn; (c) where MUR services are provided other than at an acceptable location within the meaning given in direction 4(5), they are only provided— (i) by telephone to a particular patient on a particular occasion, and (ii) in circumstances where the telephone conversation cannot be overheard (except by someone whom the patient wants to hear the conversation, for example a carer), with P having obtained the approval of the NHSCB to do so on that particular occasion; (d) subject to paragraph (2), no more than 400 MUR services consultations are carried out under the arrangements in any financial year (whether at an acceptable location or by telephone); (e) an MUR services consultation which is not triggered by concerns over patient adherence must not be offered to a patient unless the patient has been receiving pharmaceutical services from P at or from the pharmacy premises for a period of at least 3 consecutive months; (f) a patient must not have— (i) more than one MUR service consultation in any period of 12 months unless in the reasonable opinion of a registered pharmacist the patient’s circumstances have changed sufficiently to justify one or more further consultations during this period, or (ii) an MUR service consultation within 6 months of a consultation as part of a New Medicine Service, unless in the reasonable opinion of a registered pharmacist there are significant potential benefits to the patient which justify providing MUR services to them during this period; (g) at least 50% of the MUR services consultations carried out by P at or from pharmacy premises in any financial year are to be carried out with patients who are in one or more of the national target groups set out in Schedule 1; (h) P ensures that a written record of each MUR service consultation carried out by or on behalf of P is prepared by the registered pharmacist who carried out the consultation, on the approved form or in the approved manner and including the approved data (“approved” for these purposes means approved by the NHSCB); 82 03/2022 Part VIC ADVANCED SERVICES (PHARMACY AND APPLIANCE CONTRACTORS)(ENGLAND) (i) where the record mentioned in sub-paragraph (h) has to be on an approved form, P provides a copy of that form to the patient with whom the consultation to which it relates was carried out; (j) P provides information from the record mentioned in sub-paragraph (h) to the NHSCB or the Secretary of State, on request, in the manner approved for this purpose, and for the purposes approved, by the NHSCB; (k) P ensures that where— (i) MUR services are provided to a patient by or on behalf of P, and (ii) a registered pharmacist providing those services is of the opinion that it is appropriate to provide feedback about the consultation to any provider of primary medical services of which that patient is a registered patient, that feedback is provided on the approved form or in the approved manner (“approved” for these purposes means approved by the NHSCB); (l) P keeps a copy of the record mentioned in sub-paragraph (h) for at least two years after the date on which the consultation to which the record relates is carried out; (m) the NHSCB must terminate the arrangements if it is on notice that P is not, or no longer, satisfactorily complying with P’s obligations under Schedule 4 to the Pharmaceutical Services Regulations (terms of service of NHS pharmacists) in respect of the provision of essential services and an acceptable system of clinical governance; (n) MUR services are only to be provided to patients who are being prescribed more than one drug, unless the only drug they are being prescribed is a high risk medicine; and (o) P must obtain from each patient to whom P provides MUR services a signed consent form to receiving those services, which— (i) includes the approved wording as regards consent (“approved” for these purposes means approved by the NHSCB), and (ii) amongst other matters, indicates the patient’s consent to particular information, specified in the form, relating to MUR services provided to the patient being handled in the manner specified in the form (for example, for the purposes of post payment verification), and P must not provide MUR services to a patient unless the patient’s consent to that information being handled in the manner specified has been obtained. (2) As regards the first financial year during which any arrangements made with a pharmacy contractor to provide MUR services have effect, paragraph (1)(d) shall apply as if for “400” were substituted “200” if the arrangements only take effect on or after 1st October of that financial year. (3) For the purposes of paragraph (2), arrangements with P to provide MUR services at or from a particular location are to be treated as taking effect once P has— (a) notified the NHSCB (or before 1st April 2013 the relevant Primary Care Trust) in writing that P intends to start providing the MUR services; and (b) supplied the NHSCB (or before 1st April 2013 the relevant Primary Care Trust) with copies of any MUR certificates that P is required to supply in order to satisfy the condition in direction 4(4). (4) For the purposes of paragraph (1)(f)(i), a patient’s circumstances are to be treated as having changed sufficiently to justify one or more further consultations if the patient— (a) has been discharged from hospital; and (b) has had changes made to the drugs they are taking while they were in hospital. (5) A consultation as part of a New Medicine Service is not to be taken into account for the purposes of paragraph (1)(f)(ii) if since that consultation the patient— (a) has been discharged from hospital; and (b) has had changes made to the drugs they are taking while they were in hospital. 83 03/2022 Part VIC ADVANCED SERVICES (PHARMACY AND APPLIANCE CONTRACTORS)(ENGLAND) (6) A form approved by the NHSCB pursuant to paragraph (1)(h) may be in the form of an electronic record and may be sent or stored electronically (an approved manner may also provide for electronic storage and transmission of the approved data set). (7) Any approval of the Secretary of State under direction 5(1)(h), (j), (k) or (o)(i) of the 2012 Directions (MUR services: ongoing conditions of arrangements) continues in effect under the corresponding provision of paragraph (1), unless or until the approval is revoked or superseded by an approval of the NHSCB under that corresponding provision. New Medicine Service: general matters and preconditions for making arrangements 6.—(1) The NHSCB must make arrangements for the provision of a New Medicine Service with any pharmacy contractor (P) who— (a) meets the conditions set out in paragraphs (3) to (9); and (b) wishes to enter into such arrangements or is required to do so by virtue of regulation 66 of the Pharmaceutical Services Regulations (conditions relating to providing directed services). (2) The underlying purpose of a New Medicine Service is to promote the health and well being of patients prescribed with new medicines for long term conditions, in order— (a) as regards the long term conditions— (i) to help reduce symptoms and long term complications, and (ii) in particular by intervention post dispensing, to help identification of problems with management of the condition and the need for further information or support; and (b) to help the patients— (i) make informed choices about their care, (ii) self-manage their long term conditions, (iii) adhere to agreed treatment programmes, and (iv) make appropriate life style changes. (3) Condition 1 is that P has notified the NHSCB (or before 1st April 2013 the relevant Primary Care Trust) of P’s intention to provide services as part of a New Medicine Service, in the form approved for that purpose by the NHSCB. (4) Condition 2 is that P is satisfactorily complying with P’s obligations under Schedule 4 to the Pharmaceutical Services Regulations (terms of service of NHS pharmacists) in respect of the provision of essential services and an acceptable system of clinical governance. (5) Condition 3 is that— (a) if P is a registered pharmacist— (i) P has an MUR certificate, or (ii) if P intends to employ or engage a registered pharmacist to perform services as part of a New Medicine Service, that registered pharmacist has an MUR certificate; or (b) if P is not a natural person, any registered pharmacist P intends to employ or engage to perform services as part of a New Medicine Service has an MUR certificate. (6) Condition 4 is that— (a) if P is a registered pharmacist— (i) P completes in the approved manner the approved form warranting that P is competent to perform services as part of a New Medicine Service, or (ii) if P intends to employ or engage a registered pharmacist to perform services as part of a New Medicine Service, that registered pharmacist completes in the approved manner the approved form warranting that they are competent to perform services as part of a New Medicine Service; or